

1 **Single nucleus RNA sequencing reveals glial cell type-specific responses to**
2 **ischemic stroke**

3 Daniel Bormann^{1,2}, Michael Knoflach^{3,4}, Emilia Poreba⁵, Christian J. Riedl⁶, Giulia
4 Testa⁶, Cyrille Orset^{7,8}, Anthony Levilly^{7,8}, Andréa Cottureau^{7,8}, Philipp Jauk^{6,9}, Simon
5 Hametner⁶, Bahar Golabi⁵, Dragan Copic^{1,2,10}, Katharina Klas^{1,2}, Martin Direder^{1,2,11},
6 Hannes Kühntreiber^{1,2}, Melanie Salek^{1,2}, Stephanie zur Nedden¹², Gabriele Baier-
7 Bitterlich¹², Stefan Kiechl^{3,4}, Carmen Haider⁶, Verena Endmayr⁶, Romana Höftberger⁶,
8 Hendrik J. Ankersmit^{1,2*}, Michael Mildner^{5*}

9 ¹ Applied Immunology Laboratory, Department of Thoracic Surgery, Medical
10 University of Vienna, 1090 Vienna, Austria

11 ²Aposcience AG, 1200 Vienna, Austria

12 ³Department of Neurology, Medical University of Innsbruck, Anichstraße 35, 6020
13 Innsbruck, Austria

14 ⁴VASCage, Research Centre on Vascular Ageing and Stroke, 6020 Innsbruck,
15 Austria

16 ⁵Department of Dermatology, Medical University of Vienna, 1090 Vienna, Austria

17 ⁶Division of Neuropathology and Neurochemistry, Department of Neurology, Medical
18 University of Vienna, 1090 Vienna, Austria

19 ⁷Normandie University, UNICAEN, ESR3P, INSERM UMR-S U1237,
20 Physiopathology and Imaging of Neurological Disorders (PhIND), GIP Cyceron,
21 Institut Blood and Brain @ Caen-Normandie (BB@C), Caen, France

22 ⁸Department of Clinical Research, Caen-Normandie University Hospital, Caen,
23 France

24 ⁹Center for Medical Physics and Biomedical Engineering, Medical University of
25 Vienna, 1090 Vienna, Austria

26 ¹⁰Division of Nephrology and Dialysis, Department of Internal Medicine III, Medical
27 University of Vienna, 1090 Vienna, Austria.

28 ¹¹Department of Orthopedics and Trauma Surgery, Medical University of Vienna,
29 1090 Vienna, Austria

30 ¹²Institute of Neurobiochemistry, CCB-Biocenter, Medical University of Innsbruck,
31 6020 Innsbruck, Austria

32 *: contributed equally

33

34 Correspondence to:

35 Michael Mildner, PhD

36 Department of Dermatology, Medical University of Vienna

37 Lazarettgasse 14, 1090 Vienna, Austria

38 phone: +43-(0)1-40400-73507

39 e-mail: michael.mildner@meduniwien.ac.at

40 or

41 Hendrik Jan Ankersmit, MD, MBA

42 Applied Immunology Laboratory, Department of Thoracic Surgery, Medical University

43 of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.

44 e-mail: hendrik.ankersmit@meduniwien.ac.at

45

46

47

48

49

50

51

52

53

54

55 **Abstract**

56 Reactive neuroglia critically shape the brain's response to ischemic stroke. However,
57 their phenotypic heterogeneity impedes a holistic understanding of the cellular
58 composition and microenvironment of the early ischemic lesion. Here we generated a
59 single cell resolution transcriptomics dataset of the injured brain during the acute
60 recovery from permanent middle cerebral artery occlusion. This approach unveiled
61 infarction and subtype specific molecular signatures in oligodendrocyte lineage cells
62 and astrocytes, which ranged among the most transcriptionally perturbed cell types in
63 our dataset. Specifically, we characterized and compared infarction restricted
64 proliferating oligodendrocyte precursor cells (OPCs), mature oligodendrocytes and
65 heterogeneous reactive astrocyte populations. Our analyses unveiled unexpected
66 commonalities in the transcriptional response of oligodendrocyte lineage cells and
67 astrocytes to ischemic injury. Moreover, OPCs and reactive astrocytes were involved
68 in a shared immuno-glial cross talk with stroke specific myeloid cells. *In situ*,
69 osteopontin positive myeloid cells accumulated in close proximity to proliferating OPCs
70 and reactive astrocytes, which expressed the osteopontin receptor CD44, within the
71 perilesional zone specifically. *In vitro*, osteopontin increased the migratory capacity of
72 OPCs. Collectively, our study highlights molecular cross talk events which might
73 govern the cellular composition and microenvironment of infarcted brain tissue in the
74 early stages of recovery.

75

76 **Keywords**

77 Single nucleus RNA sequencing (snRNAseq), ischemic stroke, cerebral ischemia,
78 oligodendrocytes, oligodendrocyte precursor cells, astrocytes, myeloid cells

79

80

81

82

83

84

85 **Introduction**

86 The brain is among the most metabolically costly mammalian organs [72] and hence
87 particularly vulnerable to ischemia [25]. The sudden deprivation of oxygen and
88 substrate availability in the brain parenchyma triggers a cascade of complex
89 pathophysiological events, culminating in the loss of neural tissue and lasting
90 neurological dysfunction [17, 25]. In humans, this oxygen and substrate deprivation is
91 most often caused by an acute, critical reduction of cerebral blood flow, due to the
92 occlusion of large cerebral arteries, the most common cause of ischemic stroke [17].

93 Ischemic stroke is the second leading cause of disability and death worldwide and the
94 global disease burden of ischemic stroke has been predicted to increase [28]. Apart
95 from supportive care, all currently approved acute treatment strategies, that is
96 thrombolysis and mechanical thrombectomy, aim to reinstate cerebral blood flow and
97 are generally only effective when initiated within a timeframe of under 24h after stroke
98 onset [76]. Therefore, the lack of treatment strategies directed at neural tissue
99 regeneration constitute an important unmet therapeutic need. Nevertheless,
100 spontaneous, albeit typically incomplete, regain of function after stroke is common and
101 already observable within the acute phase of recovery, ranging from approximately 1
102 to 7 days [9, 20]. Numerous endogenous recovery mechanisms of the injured CNS
103 have thus been postulated [82].

104 Cerebral ischemia triggers a breakdown of neurovascular unit (NVU) integrity,
105 inflammation, neuronal cell death and white matter injury [43, 79]. This tissue damage
106 is met with pronounced transcriptional, biochemical and morphological changes in glial
107 cells, including reactive astrogliosis and early remyelination [43, 101]. However,
108 current knowledge on the phenotypic heterogeneity within each reactive cell type and
109 their precise interactions during the acute recovery from cerebral ischemic injury is still
110 limited. Single-cell sequencing technologies have proven to be highly effective in
111 addressing the challenges posed by the complex cellular heterogeneity of the CNS, in
112 health and disease [75]. Arguably, most efforts in dissecting single cell transcriptomes
113 after cerebral ischemia have been directed at immune and vascular cells [10, 16, 49,
114 58, 87, 105]. Thus far, particularly few studies have captured sufficient oligodendrocyte
115 lineage cells to identify robust subtype specific transcriptional changes following stroke
116 [35, 45]. Moreover, extensive transcriptional comparisons between reactivate

117 astrocytes and oligodendrocyte lineage cells in response to cerebral ischemia are still
118 lacking.

119 Here we generated a large-scale single nucleus transcriptome dataset of the brain's
120 acute response to ischemic stroke. We dissected subtype specific transcriptional
121 signatures of stroke reactive neuroglia, compared subtype specific astrocyte and
122 oligodendrocyte lineage cell responses and contrasted these changes with gene
123 expressional profiles found in other CNS injuries. Our study highlights common
124 immuno-glial molecular crosstalk events between myeloid cells, oligodendrocyte
125 precursor cells (OPC) and reactive astrocytes, which might shape the cellular
126 composition and microenvironment during early post ischemic neural regeneration.

127

128 **Materials and Methods**

129 **Study approval/ Ethics statement**

130 All *in vivo* animal experiments were performed in accordance with the French ethical
131 law (Decree 2013-118) and the European Union directive (2010/63/EU). The protocol
132 was submitted for ethic approval to the French Ministry of Research and the ethical
133 committee (CENOMEXA – registered under the reference CENOMEXA-C2EA – 54)
134 and received the agreement number #36435. The experiments have been reported in
135 compliance with ARRIVE 2.0 guidelines. Archived human biopsy derived brain tissue
136 material was used in agreement with the Medical University of Vienna ethics committee
137 votes: EK1636/2019, EK1454/2018).

138 **Animal husbandry**

139 All experiments were performed on male Wistar rats (6 weeks at receipt, \pm 30g, Janvier
140 Lab, Le Genest-Sainte-Isle). Throughout the experiments, animals were maintained in
141 standard husbandry conditions (temperature: $22 \pm 2^\circ\text{C}$; hygrometry: $50 \pm 20\%$), under
142 reversed light-dark cycle (light from 08:00 to 20:00), with ad libitum access to water
143 and food. Animals were housed at two per cage in the presence of enrichment.

144 **Permanent Middle cerebral artery occlusion (MCAO) model**

145 Cerebral ischemia was induced by intraluminal occlusion of the middle cerebral artery
146 (MCAO). Briefly, rats were anesthetized with isoflurane (2-2.5%) in a mixture of O₂/N₂O
147 (30%/70%). During surgery, animal temperature was monitored with a rectal probe and

148 was maintained at 37.5 °C with a heating pad. To induce permanent occlusion of the
149 middle cerebral artery (MCA) a silicone rubber-coated monofilament (size 5-0,
150 diameter 0.15mm, length 30 mm; diameter with coating 0.38 +/- 0.02 mm; Docol,
151 Sharon, MA, USA) was introduced into the lumen of the right external carotid,
152 advanced through the internal carotid, and gently pushed up to the origin of the MCA.
153 After wound stitching, the rats were returned to their home cage after receiving
154 analgesics (buprenorphine, 0.05 mg/kg, subcutaneously). In Sham operated animals
155 all experimental procedures were performed except for the filament insertion.

156 **Magnetic Resonance Imaging (MRI)**

157 To confirm successful induction of ischemic stroke and determine the anatomical
158 localization of the stroke lesion MRI was carried out 48h after stroke onset, on a
159 Pharmascan 7T MRI system, using surface coils (Bruker, Germany), following a
160 previously described approach [5]. For lesion volume evaluation, T2-weighted images
161 were acquired using a multislice multiecho sequence: TE/TR 33 ms/2500 ms. Lesion
162 sizes were quantified on these images using ImageJ software. Lesion volumes were
163 determined by a trained investigator blinded to condition and are expressed in mm³.

164 **Tissue sampling**

165 After completion of MRI studies, animals were sacrificed via sharp blade decapitation
166 in isoflurane anaesthesia, as described above. For single nucleus RNA sequencing
167 studies whole brains were extracted and swiftly cut into standardized coronal sections
168 using an adult rat brain slicer matrix (BSRAS003-1, with 3mm coronal section intervals,
169 Zivic Instruments, Pittsburgh, PA, USA) and hemispheres were separated. Coronal
170 slices, separated by hemisphere were then immediately snap frozen in liquid nitrogen
171 and stored at -80°C until further transport on dry ice.

172 For Immunofluorescence assays anesthetized animals were transcardially perfused
173 with DPBS, followed by perfusion with 4%PFA in DPBS, brains were harvested whole,
174 further post fixed overnight in 4%PFA in DPBS, and washed three times in DPBS.
175 Brains were then stored in DPBS with 0.05% Sodium Azide at 4°C until further
176 processing. To match the anatomical regions used for snRNAseq assays, brains were
177 cut into standardized coronal sections using the same adult rat brain slicer matrix
178 (BSRAS003-1), described above. After cutting, brain tissue was dehydrated and
179 embedded in paraffin.

180 **Single nuclei preparation**

181 Single nuclei suspensions were prepared as previously described [15]. Briefly, frozen
182 brain sections were thawed in ice cold Nuclei Extraction Buffer (cat#: 130-128-024,
183 Miltenyi) in gentleMACS™ C-Tubes (cat#: 130-093-237, Miltenyi Biotec, Bergisch
184 Gladbach, Germany), followed by automated gentleMACS™ Octo dissociation (cat#:
185 130-096-427, Miltenyi) using program: 4C_nuclei_1 and a further 6 min incubation on
186 ice. Suspensions were then strained into 15 ml polypropylene tubes (cat#: 430766,
187 Corning, Corning, NY, USA) over 70 µm strainers (cat#: 542070, Greiner Bio-One
188 International GmbH, Kremsmünster, Austria), 4 ml of ice cold nuclei extraction buffer
189 were added, followed by centrifugation at 500 g, 4°C, for 5 min on a swing bucket
190 centrifuge (Allegra X-12R, Beckman Coulter, Brea, CA, USA). Supernatant was
191 decanted and the pellet was resuspended in 0.25% (vol/vol) Glycerol (cat#: G5516,
192 Sigma Aldrich) and 5% (wt/vol) bovine serum albumin (BSA) (cat#A-9647, Sigma
193 Aldrich) in Dulbecco's phosphate-buffered saline (DPBS) (cat# 14190-94, Gibco,
194 ThermoFisher Scientific, Waltham, MA, USA)) (=nucleus wash buffer (NWB1), buffer
195 composition derived from [62]. Suspensions were then strained through 40 µm
196 strainers (cat#: 352340, Falcon®, Corning) and centrifuged at a swing bucket
197 centrifuge at 500 g, 4°C for 5 min. The pellet containing nuclei and debris was
198 resuspended in a Tricin-KOH buffered (pH 7.8), 10% Iodixanol solution (10% Iodixanol
199 (OptiPrep™, cat#: 7820, STEMCELL Technologies, Vancouver, BC, Canada), 25 mM
200 KCl (cat#: 60142), 5 mM MgCl₂ (cat#: M1028), 20 mM Tricin (cat#: T0377) KOH (cat#:
201 484016), 200 mM Sucrose (cat#: S0389) , all from Sigma Aldrich) and gently layered
202 on top of a 20% Iodixanol gradient cushion (20% Iodixanol, 150mM Sucrose, 25 mM
203 KCl, 5 mM MgCl₂, 20 mM Tricine-KOH, pH 7.8) in 14x89 mm thin wall polypropylene
204 centrifuge tubes (cat#: 344059, Beckman Coulter, Brea, CA, USA). An Optima L-80
205 Ultracentrifuge (serial#: Col94H18, Beckman Coulter), with swing bucket SW41 Ti
206 cartridges, precooled to 4°C was used for gradient centrifugation at 10000g, for 30 min,
207 with maximal acceleration and no brake. Following centrifugation, debris fractions were
208 discarded and the purified nuclei pellet was resuspended in ice cold NWB1 and
209 strained over 30 µm strainers (cat#: 130-098-458, Miltenyi). The suspension was
210 centrifuged at a swing bucket centrifuge at 500g, 4°C, for 5 min, supernatant was
211 discarded and nuclei were resuspended in a solution of 3% BSA, 0.125% Glycerol, in
212 DPBS (=NWB2). This washing step was repeated once. Finally, nuclei were
213 resuspended in a solution of 1.5% BSA in DPBS on ice. To obtain nuclei counts, nuclei

214 were stained using the Acridine Orange/Propidium Iodide (AO/PI) Cell Viability Kit
215 (cat#: F23001, Logos Biosystems, Anyang-si, Gyeonggi-do, South Korea). Nuclei were
216 counted as PI positive events using a LUNA-FL™ Dual Fluorescence Cell Counter
217 (cat#: L20001 Logos Biosystems). The fraction of non lysed Acridine Orange + cells
218 was <5% in all samples. All buffers used during nuclei purification were supplemented
219 with 0.2 U/μl RiboLock RNase Inhibitor (cas#: EO0384, ThermoFisher Scientific,
220 Waltham, MA, USA).

221 **Single nucleus processing and library preparation**

222 Processing of single nuclei suspensions was performed as previously described [15],
223 using the Chromium™ Next GEM Single Cell 5' Kit v2 (PN-1000263, 10 × Genomics,
224 Pleasanton, CA, USA), as per manufacturer's protocols (CG000331 Rev D,
225 10 × Genomics). In brief, for Gel Beads-in-Emulsion (GEMs) generation we loaded
226 nuclei onto Chromium™ Next GEM Chips K (PN- 1000286 ,10 × Genomics), aiming at
227 a recovery of 10-12x10³ nuclei per lane, followed by GEM reverse transcription (GEM-
228 RT) and clean up. GEM-RT products were subjected to 14 cycle of cDNA amplification
229 using 10X poly(dT) primers, followed by 10X 5' gene expression library construction.
230 The Single Index Kit TT Set A (PN 1000215, 10X Genomics) was used for sample
231 indexing during library construction. SPRIselect Reagent Kit (cat#: B23318, Beckman
232 Coulter) beads were used for clean-up procedures, as per 10X protocols instructions.
233 The quality of the obtained libraries was assessed using a DNA screen tape D5000 on
234 a TapeStation 4150 (Agilent Technologies, Santa Clara, CA, USA) and cDNA was
235 quantified using a Qubit 1xdsDNA HS assay kit (cat#: Q33231) on a QuBit 4.0
236 fluorometer (Invitrogen, ThermoFisher Scientific). Libraries with unique indices were
237 then pooled in equimolar ratios before sequencing.

238 **Sequencing, pre-processing and quality control:**

239 Samples were sequenced paired-end, with dual indexing (read length 50bp) using a
240 NovaSeq 6000 (Illumina, San Diego, CA, USA). All samples were processed on the
241 same flow cell. Raw gene counts were obtained by demultiplexing and alignment of
242 reads to the most current *rattus norvegicus* reference genome mRatBN7.2, using the
243 Cellranger v.7.0.0 pipeline, including intronic reads in the count matrix to account for
244 unspliced nuclear transcripts, as per developer's recommendations. Cellranger outputs
245 were further processed utilizing R and R Studio (R version 4.2.2, The R Foundation,
246 Vienna, Austria), using the below indicated packages. Unless otherwise stated, all

247 computational snRNAseq analyses were carried out within the environment of the
248 Seurat package v.4.3.0 [39], as per developer’s vignettes.

249 For each individual dataset UMI count matrices were generated and converted to
250 Seurat Objects, preliminary normalization and variance stabilization was performed
251 using the SCTransform, v2 regularization [21, 37], followed by PCA dimensionality
252 reduction with 50 principal components, and graph-based clustering using the
253 “RunUMAP” “FindNeighbors” and “FindClusters” commands.

254 Using the preliminary clustering information for each dataset, ambient RNA
255 contamination was estimated and ambient RNA was removed using the SoupX v1.6.2
256 package [102], following developers vignettes. The decontaminated expression
257 matrices were then further processed following the standard Seurat quality control
258 pipeline. Briefly, nuclei with < 500 UMI counts, <250 or >5000 expressed genes and
259 > 5% mitochondrial genes expressed, were removed from downstream analysis.
260 Doublets were estimated and removed using the DoubletFinder v2.0.3 package [66],
261 as per developers vignettes. All genes with less than 3 UMI counts per feature and all
262 mitochondrial genes were removed from downstream analyses.

263 **Dataset integration:**

264 After the above described quality control pipeline, normalization and variance
265 stabilization was performed for all individual datasets, utilizing SCTransform, with v2
266 regularization, with the percentage of mitochondrial reads “percent.mt” passed to the
267 “vars.to.regress” argument. All datasets were then integrated using reciprocal PCA
268 (RPCA) based integration. Briefly, the top 3000 highly variable genes were selected
269 utilizing the “SelectIntegrationFeatures” function. The datasets were then prepared for
270 integration using the “PrepSCTIntegration” function, dimensionality reduction was
271 performed for all datasets using the “RunPCA” command and integration anchors were
272 established using the “FindIntegrationAnchors” function, with RPCA reduction using
273 the first 30 dimension and the “k.anchor” argument set to 10. All datasets were then
274 integrated using the “IntegrateData” function, generating a single integrated, batch-
275 corrected expression matrix, which was used for all further downstream analyses.

276 **Clustering and subclustering of cell types:**

277 The Seurat function “RunPCA” was used for principal component analysis (PCA)
278 followed by UMAP (Uniform Manifold Approximation and Projection) dimensionality

279 reduction and Louvain clustering, using the “RunUMAP” “FindNeighbors” and
280 “FindClusters” functions. For sub clustering analysis, the clusters of interest were
281 subset, split by sample and normalization, variance stabilization and integration was
282 reiterated with the same parameters as described above. Thereafter PCA, UMAP
283 dimensionality reduction and Louvain clustering were reiterated on the reintegrated
284 and pre-processed subset to derive sub clusters.

285 **Differential gene expression analysis:**

286 The MAST statistical framework [30] within Seurat’s “FindAllMarkers” and
287 “FindMarkers” functions was used for differentially expressed gene (DEG) calculations
288 to identify cluster markers, and between group differences in gene expression, as
289 previously described [15], with minor modifications. Briefly, only genes expressed in a
290 minimum of 10% of nuclei in either tested group were considered. Log-normalized
291 RNA-counts were used for DEG analyses. The number of UMIs and the percentage of
292 mitochondrial reads, were passed to the “latent.vars” argument. For between group
293 comparison we defined a $|\log_2\text{fold change} \geq 0.6|$ and Bonferroni-adjusted p-value $<$
294 0.05 as DEG thresholds.

295 **Module score calculations:**

296 Seurat’s “AddModuleScore” function was used to calculate module scores, for
297 previously published gene sets, for each nucleus. All gene sets used are described in
298 detail in Suppl.data.file.1. Human and mouse gene symbols were converted to human
299 orthologs using the gorth tool in gprofiler2 [51], before module score calculation.
300 Estimation of cell cycle phases was conducted using Seurat’s “CellCycleScoring”
301 function, as per developer’s vignettes.

302 **Enrichment analysis**

303 Enrichment analysis was performed as previously described [15]. Briefly, rat gene
304 names of DEGs of interest were converted to human orthologs using the gorth tool in
305 gprofiler2 and used as input for Enrichr [55]. We queried the gene set databases “GO
306 Biological Process 2023”, “GO Molecular Function 2023”, “Reactome 2022” and
307 “KEGG 2021 Human”. Only enriched terms with Benjamini-Hochberg method adjusted
308 p values of <0.05 were retained.

309

310 **Cell trajectory based pseudotime inference analysis**

311 We conducted pseudotime trajectory analyses on the oligodendrocyte lineage subset
312 using Monocle3 v.1.3.1 [18, 93], following developer's vignettes. To this end we
313 converted the fully processed Seurat subset into a CDS object using the
314 "as.cell_data_set" and pre-processed the CDC object for subsequent analyses using
315 the "estimate_size_factors" and "preprocess_cds" functions at default parameters and
316 transferred the cell cluster annotations and UMAP cell embeddings from the original
317 Seurat object. Trajectory graph construction and estimation of pseudotime was
318 performed using the "learn_graph" and "order_cells" functions. The Moran's I test
319 based function "graph_test" was used to identify genes, which expressions are
320 correlated or anticorrelated in adjacent cells along the inferred pseudotime trajectory,
321 that is genes which expression changes as a function of pseudotime. "Principal_graph"
322 was passed to the neighbor_graph argument in the function, as indicated by the
323 packages developers and the obtained dataframe was subset to genes with
324 corresponding q-values <0.05 and morans I >0.05 . Thereafter, we used the
325 "find_gene_modules" function, which runs UMAP and subsequent Louvain community
326 analyses to identify co-regulated gene modules, at a resolution of 0.01. For plotting,
327 the aggregate gene expression of all genes within a respective model was generated
328 using the "aggregate_gene_expression" function.

329 **Inference of transcription factor activity**

330 We used the R package decoupleR, as per developers vignettes to infer transcription
331 factor (TF) activities [6]. Briefly, CollecTRIs' rat regulon database was retrieved via
332 Omnipath [94] using the "get_collectri" function. DecoupleR's Univariate Linear Model
333 (ulm) was run on normalized log-transformed RNA counts using the "run_ulm" function,
334 to infer transcription factor activity scores for each nucleus. Inferred transcription factor
335 activity scores were then aggregate for each cluster within each group and presented
336 as heatmaps.

337 **Cell-cell communication inference analysis**

338 To infer potential cell-cell communication (CCC) events between cell-types we used
339 the Ligand-receptor ANalysis framework (LIANA) v.0.1.12, following developer's
340 vignettes [26, 94]. Using the "generate_homologs" function LIANA's consensus CCC
341 resource entries were converted to *rattus norvegicus* ortholog gene symbols. The

342 functions “liana_wrap” and “liana aggregate” were used at default settings to infer
343 ligand receptor pairs and obtain consensus ranks across all default CCC methods
344 using Robust Rank Aggregation (RRA). Only predicted ligand receptor interactions
345 with aggregate rank scores ≤ 0.05 were retained for subsequent analyses.

346 **Visualization of bioinformatics data**

347 The following R packages were used for data visualization: Seurat v.4.3.0, Monocle3,
348 ggplot2 [98], EnhancedVolcano v.1.16.0 [12], UpSetR v.1.4.0 [22], scCustomize
349 v.1.1.1 [63], SCPubr v. 2.0.1 [11], ComplexHeatmap v. 2.14.0 [34] and pheatmap v.
350 1.0.12 [52].

351 **Human brain tissue samples**

352 Archived formalin-fixed, paraffin-embedded (FFPE) biopsy samples from 4 patients, (1
353 male, 3 females, 33 to 60 years of age) were included. Samples were graded by trained
354 neuropathologists as cerebral infarctions in the stage of macrophage resorption (Stage
355 II) and pseudo cystic cavity formation (Stage III), in accordance with previously
356 described histopathological classifications [67].

357 **Immunofluorescence staining**

358 For Immunofluorescence (IF) staining 5 μm thick rat coronal whole brain sections and
359 3 μm thick human FFPE tissue sections were cut from paraffin blocks. After
360 deparaffinization, sections were blocked in 0,9% H_2O_2 in methanol for 10 min and
361 washed three times in dd H_2O , followed by 40 min of heat induced epitope retrieval
362 (HIER) using DAKO Target Retrieval Solution pH6, or pH9 (cat# S2369, S2367, DAKO
363 - Agilent Technologies), in a Braun household food steamer. Section were allowed to
364 cool for 20min at room temperature, washed thrice in DPBS, and incubated with 1%
365 sodium borohydride (cat# 1063710100, Merck Millipore, Burlington, MA, USA) in
366 DPBS for 3 minutes to quench autofluorescence, followed by 3 washes in dd H_2O and
367 3 washes in DPBS. Sections were then blocked and permeabilized in protein-blocking
368 buffer (DPBS with 2% BSA, 10% fish gelatin (cat#: G7041, Sigma-Aldrich), 0.2%
369 Triton-X (cat# T9284, Sigma-Aldrich)) for 30 min at room temperature. For some
370 staining's we directly labelled primary antibodies using FlexAble CoraLite® Plus
371 Antibody Labeling Kits (Proteintech, Rosemont, IL, USA), as per manufacturer's
372 instructions. To colocalize antigens in tissue sections using primary antibodies derived
373 from the same host species (all rabbit derived) we used the following approach. Tissue

374 sections were incubated with the first primary antibody for 18 h at 4°C, washed three
375 times in DPBS and incubated with an appropriate secondary antibody for 1h at room
376 temperature. Thereafter sections were washed three times in DPBS and blocked with
377 10% rabbit serum in DPBS for 45 min, to block residual unbound epitopes of the
378 secondary anti-rabbit antibodies. Sections were then incubated with fluorophore
379 labeled primary antibodies for 16-18 h at 4°C, washed thrice in DPBS, incubated with
380 DAPI (cat#: 62248, ThermoFisher Scientific), at a dilution of 1:1000 for 5 minutes,
381 washed again 3 times in DPBS and 2 times in ddH₂O and finally mounted in Aqua
382 Polymount medium (cat#: 18606, Polysciences, Warrington, PA, USA). For
383 immunofluorescence assays using antibodies from different host species, all primary
384 antibodies were applied concomitantly for 16-18h at 4°C, sections were rinsed thrice
385 in DPBS, incubated with appropriate secondary antibodies for 1h at room temperature,
386 washed, DAPI counterstained and mounted as described above. 2% BSA and 5% fish
387 gelatin in DPBS was used as antibody diluent in all assays. All antibodies and labelling
388 kits used are summarized in Suppl.tab.1 and antibody combinations, dilutions and
389 corresponding HIER treatments, for all IF stainings are detailed in Suppl.tab.2.

390 **Microscopy and Quantification**

391 Sections were imaged at an OLYMPUS BX63 fluorescence microscope, with
392 motorized stage, using Olympus cellSens software (Olympus, Shinjuku, Tokyo,
393 Japan). Tissue sections were scanned at 20x magnification using cellSens' manual
394 panoramic imaging (MIA) function, with automatic shading correction, at default
395 settings. All downstream analyses were performed in QuPath [8]. Cell counts were
396 obtained in perilesional cortical grey matter and white matter regions of the ipsilateral
397 stroke lesioned hemisphere, as well as anatomically corresponding regions in the
398 contralateral hemisphere and matched section from Sham operated animals. T2
399 weighted MRI images from the same animals were used to guide the definition of
400 perilesional areas. Grey matter ROIs were defined as 1 mm² (800x1250µm)
401 rectangles, at the border of the stroke lesion. Due to the variable area and contribution
402 of large white matter tracts to the perilesional area, white matter ROIs of approximately
403 1 mm² were defined using QuPaths brush annotation tool, encompassing the corpus
404 callosum and variable portions of the external capsule. Cells were identified using the
405 Cell detection function, based on nuclear DAPI signal and intensity features, including
406 Haralick features, as well as smoothed features (Radius(FWHM)=50 µm) were

407 computed for each channel of interest on every analysed tissue section. For
408 standardized annotation of immunopositive cells, object classifiers were trained, using
409 QuPaths' random trees algorithm on at least 100 cells per tissue section, for each
410 channel. The obtained cell counts were exported and normalized to 1 mm², for
411 statistical analyses.

412 **Purification of rodent oligodendrocyte precursor cells OPC**

413 Primary rodent OPCs were purified using differential detachment as previously
414 described [15], with minor modifications. Briefly, forebrains from a total of 12 E20 fetal
415 rat cortices, derived from two timed pregnant Sprague Dawley rat dams (Charles river)
416 were separated from meninges, dissected in ice cold HBSS (cat#: 14175095, Gibco,
417 ThermoFisher Scientific) and enzymatically dissociated using Miltenyis Neural Tissue
418 Dissociation Kit (P) (cat#: 130-092-628, Miltenyi) and a gentleMACS™ Octo
419 Dissociator with Heaters (cat#: 130-096-427, Miltenyi) (program: 37C_NTDK_1), as
420 per manufacturer's instructions. Ice cold DMEM/F12 + Glutamax 4 mM (cat#:
421 31331093, Gibco, ThermoFisher Scientific), supplemented with 10% heat inactivated
422 fetal bovine serum (FBS) (cat#: 10500064, Gibco, ThermoFisher Scientific) was used
423 to stop enzymatic dissociation and the cell suspension was filtered (70 µm filters) and
424 centrifuged for 4 min at 300 g, at room temperature, on a swing bucket centrifuge. After
425 decanting the supernatant, the cell pellet was suspended in mixed neural culture
426 medium: DMEM/F12+ Glutamax 4 mM, 10% FBS, 1% Penicillin-Streptomycin (P/S)
427 (cat#: 15140122, Gibco, ThermoFisher Scientific), 1% B27 supplement (cat#:
428 17504044, Gibco, ThermoFisher Scientific). Cells were seeded in Poly-L-lysine-
429 hydrobromid (PLL) (cat#: P1524, Sigma Aldrich) coated T75 flasks (cat#:
430 CLS430641U, Corning) at a density of approximately 3.5 x 10⁶ cells per T75 flask and
431 maintained in mixed neural culture medium for 8-10 days, with media half changes
432 every 48 h. At day in vitro (DIV) 8-10 flasks were sealed air tight and shaken at 275
433 rpm, 37°C on an orbital shaker (MTS 4, IKA-Werke GmbH & Co. KG, Staufen,
434 Germany) in a humidified incubator for 1h. This step detached the majority of loosely
435 attached microglia, which were removed by a full media change with mixed neural
436 culture medium. Thereafter, the T-75 flasks were allowed to equilibrate in a humidified
437 incubator at 95%O₂/5%CO₂ for 2h, resealed and shaken at 300 rpm, 37°C for 16-18h.
438 Supernatant with detached OPCs was collected, filtered (40µm filters) and plated in
439 94/1mm non-cell culture treated petri dishes (cat#: 632181, Greiner bio-one) and

440 incubated for 50 min in a humidified cell culture incubator. Supernatant with non-
441 attached OPCs was collected, plates with attached residual microglia were discarded.
442 OPCs containing supernatant was centrifuged at 300 g for 4 min and OPCs were
443 resuspended in defined serum free OPC base medium. OPC base medium consisted
444 of DMEM/F12 + Glutamax 4 mM, 1 mM sodium pyruvate (cat#: 11360070, Gibco,
445 ThermoFisher Scientific), 10 ng/ml d-Biotin (cat#: B4639), 5 µg/ml N-Acetyl-L-cysteine
446 (cat#: A9165), 62.5 ng/ml progesterone (cat#: P8783), 5 µg/ml Insulin (cat#: I6634), 40
447 ng/ml sodium selenite (cat#: S5261), 100 µg/ml Transferrin (cat#: T1147), 100 µg/ml
448 BSA, all from Sigma Aldrich, 16 µg/ml putrescine (cat#: A18312, ThermoFisher
449 Scientific), 1% P/S and 2% B27.

450 ***In vitro* OPC migration assay**

451 2 well culture-inserts (cat#: 80209, Ibidi, Gräfelfing, Germany), in PLL coated 4 well
452 chamber slides (cat#: 354114, Falcon, Corning) were used for migration assays. 50 µl
453 OPC cell suspension at a concentration of 1×10^6 cells/ml were seeded in OPC base
454 medium, supplemented with 20 ng/ml platelet-derived growth factor A (PDGF-A) (cat#:
455 PPT-100-13A-50, Biozol, Eching, Germany), in each well. Cells were allowed to attach
456 for 16-18 h. Thereafter, the culture-insert was removed leaving a defined 500 µm cell
457 free gap. Medium was then changed to 500 µl OPC base medium (untreated control
458 (=UC)) or OPC base medium supplemented with 1 µg/ml Osteopontin (cat#: 6359-OP,
459 R&D Systems, Minneapolis, MN, USA) (OPN). After 48 h of migration cells were fixed
460 with 4% paraformaldehyde in DPBS for 20 min at room temperature and washed three
461 times with DPBS, followed by blocking and permeabilization in 2% BSA, 10% fish
462 gelatin and 0.2% Triton-X. Cy3® conjugated anti-NG2, diluted 1:50 (cat#: AB5320C3,
463 Sigma Aldrich) and CoraLite® Plus 488 conjugated Ki67, at a concentration of 2 µg/ml
464 (cat#: Ab15589, Abcam, labelled with the FlexAble CoraLite® Plus 488 Antibody
465 Labeling Kit Cat#: KFA001, Proteintech) were used to visualize OPCs and mitosis
466 committed nuclei, respectively. 2% BSA and 5% fish gelatine in DPBS was used as
467 antibody diluent and antibody dilutions were applied over night at 4°C. Thereafter cells
468 were washed three times in DPBS, incubated with DAPI (1:1000) for 5 minutes,
469 washed an additional three times in DPBS, and two times in ddH₂O before mounting
470 in Aqua Polymount medium. All NG2 positive and NG2/Ki67 double positive cells within
471 the 500 µm gap area, of each replicate, were counted at a OLYMPUS BX63

472 fluorescence microscope using Olympus cellSens software (Olympus, Shinjuku,
473 Tokyo, Japan).

474 **Bromodeoxyuridine (BrdU) incorporation assay**

475 BrdU incorporation assays were used to assess OPC proliferation *in vitro*. OPCs were
476 plated on PLL coated cover slips (cat#: CB00120RA020MNZ0, Epremedia, Portsmouth
477 NH, USA), in 24 well plates (cat#: 3527, Costar, Corning) at a density of 0.5×10^5 cells
478 per well in OPC base medium, supplemented with 20 ng/ml PDGF-A and were allowed
479 to attach and equilibrate for 24h. Thereafter, PDGF-A supplemented medium was
480 removed and cells were rinsed once in OPC base medium to remove residual PDGF-
481 A. OPCs were then treated with osteopontin at a concentration of 1 $\mu\text{g/ml}$ (OPN
482 condition) untreated OPCs in OPC base medium alone served as controls (UC
483 condition). Cells were treated for 24 h, during the last 6 h 10 μM BrdU (cat# 51-
484 2420KC) was added. Cells were fixed and permeabilized with BD Cytofix/Cytoperm
485 buffer (cat# 51-2090KE) for 20 min, washed thrice in BD Perm/Wash buffer (cat# 51-
486 2091KE) and refixed for an additional 10 min in BD Cytofix/Cytoperm buffer, followed
487 by incubation with 300 $\mu\text{g/ml}$ DNase (cat# 51-2358KC) in DPBS at 37°C for 1 h to
488 expose nuclear BrdU, as per manufacturers recommendations. All reagents from BD
489 Bioscience (Franklin Lakes, NJ, USA).

490 Cells were then washed thrice in BD Perm/Wash buffer, blocked with 2% BSA, 10%
491 fish gelatine in DPBS for 30 min and FITC conjugated anti-BrdU antibody (cat# 51-
492 2356KC, BD Bioscience), and Cy3® conjugated anti-NG2 (cat# AB5320C3, Sigma
493 Aldrich), both diluted 1:50 in 2% BSA and 5% fish gelatine in DPBS were applied. After
494 overnight incubation, cells were washed thrice in DPBS, incubated with DAPI (1:1000)
495 for 5 minutes, washed an additional 3 times in DPBS, and 2 times in ddH₂O before
496 mounting in Aqua Polymount medium. For each condition 4 cover slips were imaged
497 and NG2 positive and NG2/BrdU double positive cells in 2 random 20X magnification
498 fields of view per cover slip were counted at an OLYMPUS BX63 fluorescence
499 microscope using Olympus cellSens software.

500 **Statistical analyses**

501 For cell counts from IF stainings' in tissue sections we performed Kruskal-Wallis-H-
502 Tests, followed by Dunn's post hoc comparisons, as the data structure did not satisfy
503 the prerequisites for parametric tests. Cell counts obtained from cell culture assays

504 were analysed using unpaired Student's t-tests. Cell counts are reported as mean \pm
505 SD through the main text and represented as box plots, depicting medians, 25th to
506 75th percentiles as hinges, minimal and maximal values as whiskers, and individual
507 counts as dots throughout all respective figures. A p-value of <0.05 was set as
508 threshold for statistical significance. All statistical analyses were carried out using
509 GraphPad Prism v.9.0.0 (GraphPad Software).

510

511

512 **Results**

513 **MCAO alters CNS cell type composition and induced cell type specific** 514 **transcriptional changes**

515 Here we used a rodent model of permanent middle cerebral artery occlusion (MCAO)
516 to investigate acute cell type specific transcriptional perturbations, at single cell
517 resolution in the acute phase following cerebral ischemic injury (Fig.1a).

518 The induction of ischemic brain tissue damage was validated by MRI imaging 48 h
519 after injury (Suppl.Fig.1). Hyper intense lesions were absent from all Sham operated
520 rats (n=4), while animals from the MCAO group (n=7) exhibited pronounced ischemic
521 lesions ranging from 35.01 to 617.2 mm³, which we further stratified into moderate
522 MCAO (mMCAO) (59.6 \pm 39.2, n=3) and severe MCAO (sMCAO) (449.5 \pm 132.5, n=4)
523 infarctions (Fig.1a, Suppl.Fig.1). Selection of coronal tissue sections for snRNAseq
524 was guided by MRI imaging data. The maximum extent of the ischemic brain lesions
525 was localized approximately between Bregma anterior-posterior +1.5 mm and -2 mm,
526 in all MCAO samples, thus this region was selected for snRNAseq (Suppl.Fig.1). Left
527 and right hemispheres were sequenced separately. Hence, we obtained datasets from
528 the left and right hemispheres of Sham operated rats (Sham L and Sham R,
529 respectively), as well as left (=contralateral to ischemic lesion) and right (= ipsilateral
530 to ischemic lesions) hemispheres of mMCAO and sMCAO infarcted rats (mMCAO
531 contra, mMCAO ipsi, sMCAO contra, sMCAO ipsi, respectively) (Fig.1a).

532 After quality control, filtering and integration we recovered a total of 68616 high quality
533 nuclear transcriptomes (between 8123 and 13461 per dataset, Suppl.data.file.2), with
534 a median of 2585 UMIs and 1347 genes per nucleus. Major quality control metrics for
535 all individual datasets are reported in Suppl.Fig.2a. Following unbiased clustering

536 analysis, we first grouped all nuclei into 6 non-neuronal and 23 neuronal (12
537 glutamatergic, 1 cholinergic, 10 GABAergic) major cell clusters (Fig.1b), using well
538 established marker genes (Fig.1c). We identified three neuroglia clusters, specifically
539 one immature and one myelinating/mature oligodendrocyte lineage cluster (OLIGO_1
540 and OLIGO_2, respectively) and one astrocyte clusters (AC), as well as one
541 ependymal and mural cell cluster (EP_M_C), one vascular cell cluster, enriched for
542 endothelial and pericyte transcripts (VASC) and one myeloid cell cluster (MC).
543 Glutamatergic neurons were broadly split into *Satb2* expressing (GLU_*Satb2*+), thus
544 predominantly isocortical and *Satb2* negative, thus predominantly allocortical, and
545 deep grey matter glutamatergic neurons (GLU_*Satb2*-). As previously described
546 GLU_*Satb2*+ neurons could be well segregated using cortical layer specific markers.
547 We identified one cholinergic interneuron cluster (CHOL_IN). GABAergic neurons
548 grouped into various interneuron (GABA_IN) and medium spiny neuron populations
549 (GABA_MSN). GABA_IN were moreover separated into various *Adarb2* positive
550 (GABA_IN_*Adarb2*+), thus likely caudal ganglionic eminence (CGE) derived and
551 *Adarb2* negative (GABA_IN_*Adarb2*-), thus likely medial ganglionic eminence (MGE)
552 derived inhibitory interneuron clusters. One GABAergic cluster could not be
553 characterized using known inhibitory subset specific markers and was thus termed
554 ambiguous GABAergic neuronal cluster (GABA_Amb). A detailed description of this
555 and all following sub clustering analyses, including the curation of marker genes is
556 given in the supplementary notes.

557 Most of the clusters were represented in all datasets (Fig.1d, Suppl.Fig.2b). As
558 expected, neuronal clusters were depleted in the dataset derived from sMCAO ipsi
559 (Fig.1d, Suppl.Fig.2b). Most strikingly, almost all captured MC transcriptomes were
560 derived from the MCAO ipsi datasets. Their transcriptional signature significantly
561 overlapped with the recently established gene expression profile of stroke-associated
562 myeloid cells (SAMC) [10] (Fig.1e, Suppl.Fig.3.a) and they expressed both canonical
563 microglia and macrophage, but not lymphocyte markers (Suppl.Fig.3b). Sub clustering
564 analyses of the MC cluster revealed two microglia (MG_0, MG_1), three macrophage
565 transcript enriched (MΦe_1 to 3) and one dendritic cell (DC) cluster (Suppl.Fig.3c,d).
566 Notably, the expression of SAMC signature genes was well conserved across MG_1
567 and MΦe_1 to 3 (Suppl.Fig.3d), suggesting that microglia and macrophages converge
568 onto a common phenotype within infarcted brain parenchyma, as previously reported
569 [10]. We then systematically assessed overlaps between the gene signatures of the

570 stroke enriched myeloid cells in our datasets and previously described microglia and
571 macrophage gene expression profiles in normal development and various
572 neuropathologies. MG_1 and MΦe_1 to 3 exhibited robust enrichment for Axon Tract-
573 Associated Microglia (ATM) [38] and disease-associated microglia (DAM) but not
574 disease inflammatory macrophage (DIM) [89] associated transcripts (Suppl.Fig.3d,e).
575 Furthermore, these clusters overlapped clearly with the transcriptional phenotype of
576 “foamy” microglia enriched in multiple sclerosis (MS) chronic active lesion edges [1],
577 while the profile of iron associated, activated MS microglia [1, 84] was more restricted
578 to MΦe clusters and less prominently represented in our dataset. Likewise, the
579 upregulation of protein synthesis associated genes (e.g. *Rpl13*, *Rplp1*) typical for iron
580 metabolism associated and activated MS microglia [1, 84], was largely restricted to
581 MΦe clusters. Other MS associated myeloid cell profiles (for example associated to
582 chronic lesions, antigen presentation and phagocytosis) mapped more diffusely over
583 all myeloid cell clusters (Suppl.Fig.3e). Lastly, microglia but not macrophage enriched
584 clusters expressed proliferation associated genes (e.g. *Cdc45*, *Mki67*, *Top2a*)
585 (Suppl.Fig.3d,e). Congruently, GO terms derived from microglia sub cluster markers
586 where dominated by mitosis associated processes (Suppl.Fig.3f). Enrichment analysis
587 of MΦe cluster markers highlighted various degranulation, endo-/phagocytosis, as well
588 as iron and lipid transport and metabolism related processes (Suppl.Fig. 3f). MΦe
589 cluster markers also indicated the production of and reaction to reactive oxygen (ROS)
590 and nitrogen species (RNS) (Suppl.Fig.3f). Notably, some of the genes involved in
591 these processes (e.g. *Dab2*, *Lrp1*, *Ctsd*) were also partially enriched in MG_1
592 (Suppl.Fig.3f). Taken together these findings underpin the emergence of the SAMC
593 phenotype in the infarcted brain parenchyma and additionally highlight shared and
594 distinct transcriptional signatures of stroke associated myeloid cell subsets.

595 We next investigated transcriptional perturbations induced by cerebral ischemia within
596 those major cell clusters, which were represented in all datasets. We first compared
597 the gene expression signatures of the left and right hemisphere derived from Sham
598 control animals. As we did not identify any major differences in gene expression
599 between the two Sham hemisphere datasets (Suppl.Fig.4a,b), they were pooled in all
600 subsequent analysis. We next separately compared the datasets derived from
601 moderately and severely infarcted hemispheres (mMCAO and sMCAO ispi,
602 respectively) to the pooled Sham dataset. Both comparisons yielded a similar DEG
603 distribution, with astrocyte and oligodendrocyte lineage cells emerging as the most

604 reactive populations (Suppl.Fig.4c,d). To increase the statistical power and hence
605 robustness of our analysis we next pooled the mMCAO and sMCAO datasets and
606 performed cluster-wise comparisons against the pooled Sham and MCAO contra
607 datasets. Congruently, the majority of DEGs was derived from neuroglia clusters in
608 both DEG calculations (Fig.1f, Suppl.Fig.4e,f). With the exception of OLIGO_1 and
609 OLIGO_2, the gene expression profiles of clusters from the MCAO contra group and
610 their Sham counterparts were mostly similar (Suppl.Fig.4g). The comparisons of the
611 MCAO ipsi datasets to either Sham or MCAO contra datasets consistently unveiled a
612 higher number of DEGs in excitatory neuronal clusters, as compared to inhibitory
613 neuronal clusters (Fig.1f, Suppl.Fig.4.c-f, Suppl.Fig.5a,b). However, within the MCAO
614 ipsi dataset we noticed the emergence of a canonical cellular stress response
615 signature [31], marked by the upregulation of several heat shock proteins (e.g. *Dnaja1*,
616 *Hsp90aa1*, *Hspa8*, *Hsph1*) in GABA_Amb (Suppl.Fig.5b). This signature mapped to a
617 discrete subset of this cluster, which upon unsupervised subclustering analysis was
618 revealed to be carried exclusively by misclustered oligodendrocytes but not neurons
619 (Suppl.Fig.5c,d). Hence, this cluster did not disclose a set of neurons with particular
620 vulnerability to ischemia, but rather underpinned the responsiveness of neuroglia to
621 ischemic injury. A full list of DEGs per cell cluster across all mentioned comparisons is
622 provided in Suppl.data.file.3.

623 **Single nucleus transcriptomics identifies stroke specific oligodendrocyte** 624 **lineage cell populations**

625 Neuroglia are known drivers of regenerative mechanisms following stroke [43, 101],
626 consist of highly heterogeneous subpopulations and ranged among the most
627 transcriptional perturbed cell populations within our dataset. Therefore, we interrogated
628 these cell populations in more detail. We first jointly sub clustered OLIGO_1 and
629 OLIGO_2. After manual removal of two clusters with evident neuronal transcript
630 contamination (Suppl.Fig.6a-d), 10 sub clusters remained, which could be largely
631 grouped according to canonical developmental stages of the oligodendrocyte lineage
632 trajectory. Specifically, we identified two oligodendrocyte precursor cell clusters
633 (OPC_0, OPC_1), one committed oligodendrocyte precursor cell cluster (COP), one
634 newly formed oligodendrocyte cluster (NFOLIGO), two myelin forming oligodendrocyte
635 clusters (MFOLIGO_1 and MFOLIGO_2) and three mature oligodendrocyte clusters
636 (MOLIGO_1 to MOLIGO_3) (Fig.2a). Lastly, one sub cluster faintly expressed markers

637 of oligodendrocytes and immune cell associated genes (Fig.2a). Strikingly, the majority
638 of immune cell transcripts, within this sub cluster was derived from the MCAO ipsi
639 datasets (Suppl.Fig.6e, Supplementary notes). Importantly, previous research has
640 shown that oligodendrocyte transcripts accumulate in the nuclear compartment of
641 phagocytic myeloid cells, giving rise to clusters expressing both oligodendrocyte and
642 myeloid cell transcripts *in vivo* [84]. This cluster was thus annotated myeloid cell
643 oligodendrocyte mixed cluster (MC_OLIGO). Details on marker gene curation are
644 given in the supplementary notes, a full list of subcluster markers is provided in
645 Suppl.data.file.2.

646 Notably, the two subclusters, OPC_1 and MOLIGO_1, were predominantly derived
647 from infarcted brain tissue of sMCAO and to a lesser extent from mMCAO (Fig.2a,
648 Suppl.Fig.6f,g). Pseudotime trajectory analysis indicated that the stroke specific sub
649 cluster OPC_1 branched directly from the conserved sub cluster OPC_0 (Fig.2b). As
650 expected, the mature oligodendrocyte clusters were associated to the highest pseudo
651 time values. We identified a prominent trajectory bifurcation within MOLIGO_0, with
652 one stroke specific branch encompassing MOLIGO_1 and one branch extending to
653 MOLIGO_2, which was conserved across all groups. Notably, cell cycle scoring
654 revealed that sub cluster OPC_1 was derived from proliferating cells (Fig.2b).

655 We next conducted DEG calculations for the oligodendrocyte lineage subclusters
656 which were conserved across all groups. (Suppl.Fig.7). Remarkably, the gene
657 expression profiles of the conserved clusters differed little between the infarcted and
658 contralateral hemisphere, with the exception of MC_OLIGO (Suppl.Fig.7a), which was
659 enriched in immune process and myeloid cell associated genes in MCAO ipsi as
660 described above (Suppl.Fig.6e). Likewise, the gene expression profiles of most
661 conserved clusters were similar in the MCAO ipsi and Sham datasets, with the notable
662 exception of OPC_0 (Total DEG: 50), MOLIGO_0 (Total DEG: 185) and MC_OLIGO
663 (Total DEG: 98) (Suppl.Fig.7b). Interestingly, MOLIGO_0 emerged as the only cluster
664 with notable transcriptional perturbation from the comparison of the MCAO contra to
665 the Sham datasets (Total DEG: 119) (Suppl.Fig.7c). Importantly, 102 [96,23%] of the
666 downregulated DEGs in the MOLIGO_0 subcluster in MCAO contra relative to Sham,
667 were also identified in the comparison of MCAO ipsi to Sham (Suppl.Fig.7d) and
668 contained neurexins and neuregulins (e.g. *Nrxn1*, *Nrxn3*, *Nrg1*, *Nrg3*), as well as genes
669 encoding neurotransmitter receptors, ion channels and ion channel interacting proteins

670 (e.g. *Kcnip4*, *Grm5*, *Kcnq5*) (Suppl.Fig.7e). Of note, the downregulation of many of
671 these genes was subtle in terms of gene expression, as they were a priori expressed
672 at low levels in the Sham dataset within the oligodendrocyte lineage clusters
673 (Suppl.Fig.7e). All DEGs, derived from all mentioned comparisons are reported in
674 Suppl.data.file.4.

675 We next interrogated how the MCAO ipsi specific sub clusters (OPC_1 and
676 MOLIGO_1) differed transcriptionally from their homeostatic counterparts, via DEG
677 analyses. Comparisons of OPC_1 to OPC_0 and MOLIGO_1 to MOLIGO_2 yielded a
678 total of 519 and 384 DEGs, respectively (Fig.2c, Suppl.data.file.4). Notably, the OPC_1
679 and MOLIGO_1 DEG signature was identified in both mMCAO ipsi and sMCAO ipsi
680 datasets (Suppl.Fig.6h,i). To gain insight into how the stroke specific OPC_1 and
681 MOLIGO_1 gene expression signatures might relate to changes in biological function
682 we performed enrichment analyses (summarized in Suppl.data.file.5). We also
683 systematically compared the signatures of OPC_1 and MOLIGO_1 to each other and
684 to gene expression profiles of diseases associated oligodendrocytes (DAO), derived
685 from various rodent models of neurodegeneration and demyelination [73] (Suppl.Fig.8,
686 Supp.data.file.1). Transcriptional overlaps between stroke specific oligodendrocyte
687 lineage sub clusters with DAO profiles were generally limited (Suppl.Fig.8). The vast
688 majority of OPC_1 enriched genes mapped to cell cycle progression and proliferation
689 associated terms (Fig.2d, Suppl.data.file.5). Enrichment analyses further highlighted,
690 the upregulation of several intracellular scaffold proteins and protein-kinases involved
691 in OPC cell adhesion, migration, survival and differentiation, such as *Iqgap1* [71], *Met*
692 [4], *Fyn* [54], or *Axl* [85] and indicated extensive interactions of OPC_1 with the
693 extracellular matrix (ECM) (Fig.2d). Notably, the canonical pan-reactive astrocyte
694 markers *Cd44* and *Vim* [59, 103], as well as *Runx1* were enriched in both DAO and
695 OPC_1. *Runx2* was likewise upregulated in OPC_1, as well as the neuroprotective
696 immunomodulatory alarmin *Il33* [100]. Interestingly, both *Vim* and *Il33*, have previously
697 been shown to be upregulated upon injury in various oligodendrocyte lineage cells [32,
698 50]. Notably, several growth factors, such as *Ccnf*, *Vgf* and *Fgf2* were also upregulated
699 in OPC_1. Conversely, we observed a downregulation of synaptic transmission
700 associated transcripts, particularly concerning potassium and glutamate homeostasis
701 in OPC_1 (Fig.2d).

702 Interestingly, multiple biological processes associated to MOLIGO_1 enriched DEGs,
703 for example Axonogenesis (GO:0007409), or Axon Guidance (R-HSA-422475)
704 (Suppl.data.file.5), relate to the modulation of neuritogenesis. Several genes
705 encompassed by these gene sets, such as multiple upregulated sempahorines, have
706 more extensive pleiotropic roles in physiological CNS development and pathology [19].
707 Similar to OPC_1 several MOLIGO_1 enriched DEGs were associated to ECM
708 interactions and glycosaminoglycan (GAG) metabolism (Fig.2d). Many of the
709 MOLIGO_1 enriched DEGs (e.g. *Dlg1*, *Lamc1*, *Psem4*, *Sema5b*, or *Cadm1*) were also
710 expressed in less mature oligodendrocyte sub clusters, but absent in the mature
711 oligodendrocyte populations MOLIGO_0 and MOLIGO_2, in the Sham and MCAO
712 contra datasets. Congruently, the expression of the canonical COP and NFOLIGO
713 marker *Bcas1* [29] was markedly higher in MOLIGO_1 as compared to MOLIGO_0
714 and MOLIGO_2. Thus, several markers of more immature oligodendrocyte
715 developmental stages were uniquely upregulated in MOLIGO_1, but not other mature
716 oligodendrocyte clusters. Several MOLIGO_1 enriched DEGs were related to Notch,
717 TGF- β and IGF-1 signalling, but also included more elusive signalling molecules, like
718 the TIR-domain-containing adaptor (TRIF) recruiter *Wdfy1* [41] (Fig. 2d). Notably,
719 several of the genes associated to Notch signalling by enrichment analyses, such as
720 *Il6st* and *Stat3* are also crucially involved in multiple type I cytokine signalling pathways
721 [69].

722 Regarding putative metabolic changes, we noted a robust upregulation of the 6-
723 phosphofructo-2-kinase/fructose-2,6-biphosphatase isozyme 3 and 4 coding genes
724 *Pfkb3*, *Pfkb4*, signifying a state of increased anaerobic glycolysis [61]. This was
725 accompanied by a downregulation of aspartate/asparagine metabolism related
726 transporters (e.g. *Slc25a13*) and enzymes (e.g. *Folh1*, *Aspa*) and P-Type ATPases
727 involved in lipid translocation (*Atp10a,11a,11b*). Moreover, myelination associated
728 genes were discreetly downregulated in MCAO ipsi derived MOLIGO_1 transcriptomes
729 as compared to MOLIGO_2 (Fig.2c,d).

730 Complementary to the calculation of DEGs between a priori defined clusters, we
731 identified genes which changed dynamically as a function of pseudo time and
732 combined them into co-regulated gene modules using Monocle 3 (see Materials and
733 Methods) (Fig.2e). Remarkably, 5 modules mapped uniquely to stroke specific sub
734 clusters and mainly consisted of genes which were also identified as OPC_1 or

735 MOLIGO_1 enriched DEGs (Fig.2e, Suppl.data.file.6). Interestingly, the OPC_1
736 associated modules 4 and 11 consisted mainly of proliferation related genes and
737 mapped over the entire OPC_1 cluster. By contrast, module 5, which contained ECM-
738 interaction, migration, survival and immunomodulatory process associated genes
739 appeared further down on the pseudo temporal trajectory. The aggregate rank score
740 of module 9 increased with incremental distance to the trajectory bifurcation within
741 MOLIGO_0, indicating a dynamic progression from MOLIGO_0 towards MOLIGO_2
742 specifically within infarcted tissue. This module was permeated by abundant ECM and
743 cell-cell interaction associated genes (e.g. *Adamts1*, *Cadm1*, *Cldn14*, *Col12a1*), as
744 well as other genes previously identified as MOLIGO_1 markers during DEG analysis,
745 as described above (e.g. *Stat3*, *Wdfy1*).

746 Additionally, we inferred transcription factor (TF) activities using a molecular foot print
747 based approach [6]. In congruence with the previous analyses several TFs for which
748 increased activation was inferred within OPC_1 pertained to proliferation and survival
749 associated pathways, for example E2f1, or Myc [64] (Fig.2f). Notable, TFs with
750 increased activity in MOLIGO_1 included the hypoxia response related basic helix-
751 loop-helix/Per-ARNT-SIM (bHLH-PAS) superfamily members Ahr and Hif1 α [53] and
752 the STAT family members Stat3 and Stat5a. Conversely, the inferred activity of multiple
753 hallmark TFs of oligodendrocyte differentiation and myelination, such as Olig1 [24],
754 Nkx2-2 [77], or Rxrg [42] was decreased in the MCAO ipsi derived MOLIGO_1 nuclei
755 (Fig.2f). In summary, using multiple complementary bioinformatics approaches we
756 described the emergence of two transcriptionally unique oligodendrocyte lineage
757 clusters within the infarcted hemisphere, marking the most robust cerebral ischemia
758 induced change within the oligodendrocyte lineage.

759 **Proliferating, VIM and IL33 positive OPCs accumulate at the perilesional zone**

760 We next conducted IF staining to confirm the presence of stroke associated
761 proliferating OPCs *in vivo* and interrogated their spatial distribution in the MCAO
762 infarcted brain, 48h after stroke (Fig.3). Overall, mitosis committed OPCs (NG2⁺/Ki67⁺)
763 were almost absent in cortical grey matter (GM) and large white matter (WM) tracts of
764 Sham operated animals, sparse in the hemisphere contralateral to the infarct lesion,
765 but abundant in the perilesional grey and white matter surrounding the ischemic lesion
766 (Fig.3). Furthermore, a substantial number of mitotic OPCs was also positive for VIM
767 and IL33 (Fig.3), as predicted by snRNAseq analysis (Fig.2).

768 Specifically, while essentially absent in the GM and WM of Sham operated rats (GM:
769 $0/\text{mm}^2$; WM: $1.05 \pm 1.2/\text{mm}^2$) and the hemisphere contralateral to infarction (GM:
770 $0.3 \pm 0.5/\text{mm}^2$; WM: $0.9 \pm 1.1/\text{mm}^2$) the number of NG2⁺/VIM⁺/Ki67⁺ triple positive OPCs
771 increased significantly in the perilesional GM ($53.9 \pm 18.3/\text{mm}^2$) and WM
772 ($18.6 \pm 5.1/\text{mm}^2$) (Fig.3a-c).

773 Likewise, virtually no NG2⁺/IL33⁺/Ki67⁺ triple positive OPCs were found in the grey and
774 white matter of Sham operated and contralateral MCAO brains (Fig.3d-f). In contrast,
775 the number of NG2⁺/IL33⁺/Ki67⁺ triple positive OPCs in the perilesional GM increased
776 significantly as compared to corresponding Sham GM ($35.7 \pm 26.3/\text{mm}^2$) (Fig.3f).
777 Similarly, no NG2⁺/IL33⁺/Ki67⁺ triple positive OPCs were identified in the WM of Sham
778 operated animals, or the WM contralateral to infarction, while they were abundant in
779 perilesional WM ($17.00 \pm 5.5/\text{mm}^2$) (Fig.3d-f). Statistical comparison of all subsets within
780 all ROIs is reported in Suppl.data.file.7.

781 Collectively, these findings confirmed that mitotic OPCs distinctly accumulate in both
782 the perilesional WM and GM, 48h after MCAO and a substantial subset of these OPCs
783 expresses the snRNAseq predicted, injury associated markers VIM and IL33.

784 **Transcriptional heterogeneity of reactive astrocytes in the infarcted brain**

785 Similar to our investigation into the heterogeneous responses to stroke in
786 oligodendrocyte lineage subsets we performed subclustering analysis for astrocytes.
787 After removal of contaminating clusters (Suppl.Fig.9), we identified 5 astrocyte sub
788 clusters. 2 sub clusters (AC_1 and AC_2) exhibited robust expression of homeostatic
789 astrocyte associated genes such as *Gpc5*, *Kirrel3*, *Cdh10* or *Trpm3* [1, 36, 84]. These
790 clusters were identified in all datasets, although their relative abundance decreased
791 slightly in the contralateral hemisphere of MCAO operated rats and substantially in the
792 ipsilateral, infarcted hemisphere (Fig.4a). Conversely, in three subclusters (AC_3 to
793 AC_5) these homeostatic astrocyte markers were expressed more faintly, while they
794 were enriched for pan reactive astrocyte markers such as *Gfap*, *Vim*, *Osmr*, *Cd44*, or
795 *Cp* [59, 103] (Fig.4a). These three clusters were virtually absent from Sham datasets,
796 sparsely represented in datasets of the contralateral MCAO hemisphere, abundant in
797 infarcted hemispheres (Fig.4a, Suppl.Fig.9e) and thus were annotated as reactive
798 astrocyte clusters. Further details on marker gene curation are given in the
799 supplementary notes. Of note reactive astrocytes were more abundant in the datasets
800 derived from severe, compared to moderate infarctions (Suppl.Fig9f). To characterize

801 these reactive astrocyte populations in more detail, we compared each reactive
802 astrocyte cluster to the homeostatic subclusters (AC_1 and AC_2) using DEG
803 analyses (Fig.4b, Suppl.data.file.8). Notably, the DEG signature of AC_3 was
804 prominent in both moderate and severe infarctions, while the AC_4 and AC_5 reactive
805 astrocyte signature was predominately derived from severe infarctions (Suppl.Fig.9g-
806 i). Inference of functional characteristics from the DEGs of the reactive astrocyte
807 subclusters (AC_3 to AC_5), using enrichment analyses highlighted notable
808 communalities, particularly between the gene signatures of AC_3 and AC_4 (Fig. 4c,
809 Suppl.data.file.9). For instance, tight (e.g. *Tjp1*, *Tjp2*) and adherence (e.g. *Vcl*) junction
810 components related to blood brain barrier maintenance were upregulated in both AC_3
811 and AC_4. Furthermore, several upregulated DEGs in AC_3 and AC_4 related to
812 various ECM interaction, wound healing and cell motility and migration related terms
813 to varying degrees. For example, some cadherin binding related genes (e.g. *Cald1*,
814 *Cdh2*) were more enriched in AC_3, matrix metalloprotease coding genes (e.g.
815 *Adamts1*, *Adamts9*) were upregulated in both, as was *Cd44*, and various Integrin family
816 member (e.g. *Itga1*, *Itga5*). Various reactive astrocyte derived DEGs related to axon
817 guidance and neural cell migration, such as *Sema3c* [81] in AC_3 or *Robo2* [47] in
818 AC_4. Other related to VEGF response (e.g. *Nrp2*, *Rock2*, *Hspb1*) predominantly in
819 AC_4 and chemokine signalling (e.g. *Ccl2*, *Shc3*, *Shc4*) predominately in AC_3.
820 Overall the transcriptional signature of AC_3 and AC_4 suggest a complex injury
821 response, marked by ECM reorganization, increased migration and involvement in
822 bidirectional communication with other brain parenchymal and infiltrating cell types.
823 AC_5 lacked several of the aforementioned transcriptional features of AC_3 and AC_4,
824 but shared the upregulation of several pan reactive astrocyte markers such as *Gfap*,
825 *Cp*, or *Vim* with the other reactive astrocytes (Fig.4a, Suppl.Fig10a). The most
826 distinguishing characteristic of AC_5 was the enrichment of several gene sets related
827 to cilium and axonemal assembly and movement, including the ciliogenic transcription
828 factor *Rfx3*, cilium dynein arm (e.g.*Dnah9*), or central pair (e.g. *Cfap46*, *Cfap54*)
829 elements [44] (Fig. 4d). Of note this profile was identified in the AC_5 cluster in MCAO
830 ipsi and MCAO contra.

831 Multiple glutamate (e.g. *Grin2c*, *Gria2*) and GABA (e.g. *Gabrb1*, *Gabrg1*) receptors,
832 glutamate (e.g. *Slc1a2*) and GABA (e.g. *Slc6a11*) reuptake transporters and other
833 solute carrier (SLC) transporters, involved in amino acid import (e.g. *Slc7a10*) were
834 robustly downregulated in all reactive astrocyte subclusters (Fig.4e). Several genes

835 related to lipid metabolism (e.g. *Acs/3*, *Acs/6*) and lipid transport (e.g. *Abca1*, *Apoe*)
836 were particularly downregulated in AC_3. Genes involved in synapse assembly and
837 maintenance, such as *Gpm6a* were downregulated in all reactive astrocyte subsets to
838 various degrees. To summarize, reactive astrocytes lost homeostatic gene signatures
839 related to neurotransmitter and lipid metabolism, as well as synapse maintenance in
840 infarcted brain tissue.

841 The inference of TF activities unveiled further shared patterns in reactive astrocytes.
842 Notable examples of TFs with increased activity in reactive astrocytes related to STAT
843 signalling (e.g. *Stat3*, *Stat5a/b*), proliferation, growth and survival (e.g. *E4f1*, *Myc*, *Jun*,
844 *Fos*, *Fosl2*), response to hypoxia (e.g. *Hif1a*) and growth factors (e.g. *Egr1*) [88], or
845 *Snai1*, which was recently implicated in the TGF-beta induced glial-mesenchymal
846 transition of Müller glia [46]. Notably, increased activity for multiple of these TFs (e.g.
847 *Stat5a*, *Stat3*, *Myc*, *Hif1a*, *Snai1*) was also observed in stroke specific Oligodendrocyte
848 subsets (Fig.2f). Congruent with the upregulation of primary cilium associated genes,
849 increased activity of the ciliogenesis master regulator *Foxj1* [44] was inferred for AC_5.

850 Next we compared the transcriptional signatures of the stroke associated reactive
851 astrocytes within our dataset to gene expression profiles of reactive astrocytes found
852 in other neurodegenerative and inflammatory neuropathologies (Suppl.Fig.10). Pan-
853 reactive [59] and neurodegenerative disease associated astrocyte (DAA) [36]
854 signatures, mapped to several stroke reactive astrocyte subsets (Suppl.Fig.10a,c-d).
855 No stroke reactive astrocyte subset in our dataset matched the inflammatory,
856 neurotoxic A1 phenotype, while the neuroprotection associated A2 signature [59, 103]
857 partially overlapped with the signature of AC_3 (Suppl.Fig.10d). Among the reactive
858 astrocyte populations identified in MS (MS_AC_reactive) by Absinta et al. [1], the
859 MS_AC_reactive_1&5 subsets, originally described as “reactive/stressed astrocytes”
860 partially overlapped with the stroke reactive astrocyte clusters AC_3 and AC_4 of our
861 dataset (Suppl.Fig.10c,d). Overlaps with the “astrocytes inflamed in MS” (MS_AIMS)
862 signature were sparse and mainly restricted to pan reactive astrocyte genes (e.g. *Vim*,
863 *Gfap*) (Suppl.Fig.10c,d). Interestingly, 25 (19.38%) of the 129 DEGs upregulated in
864 AC_5 were also included in MS_AC_reactive_4, originally described as “senescent
865 astrocytes” [1] (Suppl.Fig.10c). However, these overlaps did not consist of genes
866 related to senescence, but almost exclusively ciliary process associated genes.
867 Remarkably, the gene expression profiles of reactive astrocytes and stroke specific

868 oligodendrocyte lineage subsets within our dataset shared extensive similarities
869 (Suppl.Fig.10e). Particularly, we observed that 66 of the 351 DEGs (18.8%)
870 upregulated in OPC_1 and 24 of the 216 DEGs (11.11%) upregulated in MOLIGO_1
871 were also upregulated in the reactive astrocyte cluster AC_3 (Suppl.Fig.10e).

872

873 **Cell-cell communication (CCC) inference analysis implicates glycoproteins as** 874 **major immuno-glial signalling hubs in infarcted brain tissue**

875 So far we identified transcriptionally unique myeloid and neuroglial subsets within
876 infarcted brain tissue. Therefore, we next interrogated the molecular cross talk
877 between these cells by inferring potential ligand receptor (LR) interactions, using
878 LIANA. We only retained the most robust interactions (aggregate rank score ≤ 0.05)
879 (Suppl.data.file.10) and extracted LR pairs unique to datasets from MCAO ipsi.
880 Intriguingly, we inferred 129 LR pairs specific to infarcted brain tissue and grouped
881 them into immuno-glial (Suppl.Fig.11a-e) and intra-glial (Suppl.Fig.12a-e) interactions.
882 These interactions corroborated multiple recently inferred stroke response signalling
883 axes, for example between microglia and oligodendrocyte lineage subsets (e.g. *Igf1-*
884 *>Igf1r*, *Thbs1->Cd47*, *Psap->Gpr37*) [45]. Interestingly, within infarcted tissue
885 specifically, macrophage enriched myeloid cell clusters (MΦe) were predicted to signal
886 abundantly via Fibronectin (*Fn1*) onto both myeloid and neuroglia subsets
887 (Suppl.Fig.11b-d). Cell surface glycoproteins, such as myelin associated glycoprotein
888 (*Mag*), various integrin and syndecan family members and CD44 were the most
889 commonly predicted Fibronectin receptors on myeloid and neuroglial cells
890 (Suppl.Figs.11-12). Notably, astrocytes were also predicted to signal via fibronectin ->
891 glycoprotein receptor signalling onto various myeloid and neuroglial subsets
892 (Suppl.Figs.11e-12d,e). Glycoprotein receptors indeed emerged as signalling hubs on
893 various myeloid and neuroglial subsets. For instance, Cd44 was inferred to be targeted
894 by various ECM associated ligands such as fibronectin (*Fn1*), various collagens (e.g.
895 *Col4a1*, *Col6a3*), *Spp1* encoding osteopontin, but also growth factors, such as
896 hepatocyte growth factor (*Hgf*) or heparin-binding EGF-like growth factor (*Hbegf*)
897 (Suppl.Figs.11-12). Strikingly, microglia and macrophage derived *Spp1* was predicted
898 to signal back to both myeloid subsets, as well as stroke specific OPCs (OPC_1) and
899 stroke reactive astrocytes (AC_3 and AC_4) via *Cd44* (Suppl.Figs.11b-d).

900 **Cd44 positive reactive astrocytes and proliferating OPCs accumulate at the**
901 **lesional rim in close proximity to osteopontin positive myeloid cells**

902 CD44 was identified as a particularly robust marker of reactive astrocytes, in various
903 neuropathological contexts [65] and our dataset (Fig.4, Suppl.Fig.10). Surprisingly, we
904 also detected a pronounced upregulation of *Cd44* in stroke associated, proliferating
905 OPCs (Fig.2). Moreover, *Spp1* -> *Cd44* signalling events from myeloid cells to stroke
906 specific OPCs, reactive astrocytes and myeloid cells themselves ranged among the
907 most robustly predicted interactions within our CCC analysis (Suppl.Figs.11-12). We
908 reasoned that these cell populations might distinctly spatially colocalize in the infarcted
909 brain, a hypothesis we interrogated using IF stainings.

910 Indeed, the number of GFAP⁺/CD44⁺/VIM⁺ reactive astrocyte was significantly higher
911 in perilesional cortical GM ($123.6 \pm 107.9/\text{mm}^2$) as compared to the contralateral GM
912 in MCAO operated rats ($4.2 \pm 3.9/\text{mm}^2$) and the GM of Sham operated rats ($2.8 \pm$
913 $3.3/\text{mm}^2$) (Fig.5a-c). Likewise, GFAP⁺/CD44⁺/VIM⁻ astrocytes were significantly more
914 abundant in perilesional ($41.4 \pm 21.9/\text{mm}^2$) as compared to contralateral MCAO group
915 GM ($4.2 \pm 6.1/\text{mm}^2$). Comparison of cell numbers in perilesional to Sham ($5.3 \pm$
916 $3.3/\text{mm}^2$) GM approached significance (Fig.5c). CD44 was previously implicated as a
917 WM astrocyte subset marker [84]. Congruently, GFAP⁺/CD44⁺/VIM⁻ astrocytes were
918 found in all imaged WM ROIs (Sham: $120.3 \pm 64.9/\text{mm}^2$; MCAO contra:
919 $116.9 \pm 101.8/\text{mm}^2$; MCAO ipsi: $301.4 \pm 485.7/\text{mm}^2$) and did not differ significantly
920 between groups. However, the abundance of GFAP⁺/CD44⁺/VIM⁺ astrocytes in the
921 perilesional WM ($626.0 \pm 306.8/\text{mm}^2$) increased significantly as compared to MCAO
922 contra ($88.4 \pm 35.9/\text{mm}^2$) and comparison to Sham WM ($120.0 \pm 44.04/\text{mm}^2$) approached
923 significance (Fig.5c).

924 Proliferating CD44 positive OPCs (NG2⁺/CD44⁺/Ki67⁺) were essentially absent from
925 the GM or WM of Sham treated rats (GM: 0, WM: $0.25 \pm 0.5/\text{mm}^2$) or the hemisphere
926 contralateral to infarction (GM: 0, WM:0), while they were significantly more abundant
927 in perilesional GM ($44.3 \pm 23.7/\text{mm}^2$) and WM ($12.3 \pm 10.2/\text{mm}^2$) (Fig. 5d-f).

928 In summary, both reactive astrocytes (GFAP⁺/CD44⁺/VIM⁺) and proliferating CD44
929 positive OPCs (NG2⁺/CD44⁺/Ki67⁺) accumulated in the perilesional zone surrounding
930 the infarcted tissue.

931 Within the same region we identified abundant OPN positive myeloid cells
932 (Iba1⁺/OPN⁺) (Fig.6a-c). Specifically, the number of Iba1⁺/OPN⁺ cells within the
933 perilesional GM ($161.3 \pm 44.4/\text{mm}^2$) was significantly higher as compared to the GM
934 contralateral to infarction ($11.6 \pm 9.4/\text{mm}^2$) or the GM of Sham operated rats
935 ($17.3 \pm 18.4/\text{mm}^2$) (Fig.6c). Likewise, significantly more Iba1⁺/OPN⁺ cells were identified
936 in the perilesional WM ($226.3 \pm 135.3/\text{mm}^2$) as compared to the WM contralateral to
937 infarction ($11.385 \pm 18.25/\text{mm}^2$) and the comparison to Sham WM ($11.6 \pm 9.5/\text{mm}^2$)
938 approached statistical significance (Fig.6c). Notably, a substantial amount of OPN
939 expressing myeloid cells was themselves CD44 positive (Fig.6a-c). In fact, the number
940 of Iba1⁺/CD44⁺/OPN⁺ triple positive myeloid cells was significantly higher in the
941 perilesional GM ($142.0 \pm 47.5/\text{mm}^2$) as compared to the corresponding GM in the
942 hemisphere contralateral to infarction ($1.8 \pm 2.4/\text{mm}^2$) or in the GM of Sham operated
943 rats ($2.3 \pm 2.6/\text{mm}^2$). Likewise, more Iba1⁺/CD44⁺/OPN⁺ cells were identified in the
944 perilesional WM ($183.05 \pm 133.3/\text{mm}^2$) as compared to the WM contralateral to
945 infarction ($2.4 \pm 3.02/\text{mm}^2$) and the comparison to Sham WM ($3.1 \pm 2.6/\text{mm}^2$)
946 approached statistical significance. Of note, a considerable proportion of CD44 positive
947 myeloid cells was undergoing mitosis within the perilesional zone (Suppl.Fig.13a-c).
948 Statistical comparison of all subsets within all ROIs is reported in Suppl.data.file.7.
949 Interestingly, the spatial association of OPN positive myeloid cells to bordering CD44
950 positive cells was also observed in human cerebral infarctions in the stage of advanced
951 macrophage resorption (Suppl.Fig.14a-d).

952 **Osteopontin induces OPC migration but not proliferation *in vitro***

953 Osteopontin to CD44 signaling ranged among the most robust inferred immunogial
954 cell-cell interaction events in our dataset (Suppl.Figs.11,12). Importantly, increased
955 cellular motility and migration are well-established functional consequence of
956 osteopontin -> CD44 signaling in multiple cell populations [27, 56]. Interestingly, we
957 observed that OPN positive myeloid cells and CD44 positive neuroglia accumulated at
958 the perilesional zone in close proximity *in situ* (Fig.6). We thus speculated that OPN
959 might increase the migratory capacity of neuroglial cells. Indeed, OPN was shown to
960 induce migration in astrocytes *in vitro* [95]. We wondered whether OPN exerts similar
961 effects on OPCs, which was thus far not shown. A cell gap migration assay revealed
962 that the number of OPCs which migrated into the central gap was significantly
963 increased upon OPN treatment (Fig.7a). To exclude that the increased cell number

964 within the central gap 48h after OPN treatment was caused by enhanced cell
965 proliferation we quantified Ki67 positive cells. The number of Ki67 positive cells within
966 the central gap did not differ significantly between OPN treated and untreated OPCs
967 (Fig.7a). We followed up on this observation using a BrdU incorporation assay, as a
968 more sensitive measurement of cell proliferation. Consistently, OPN did not increase
969 the percentage of BrdU positive cells (Fig.7b). In summary, OPN induces migration but
970 not proliferation of OPCs *in vitro*.

971

972 **Discussion**

973 Reactive astrogliosis is an extensively researched hallmark of the brain's wound
974 healing response following cerebral ischemia [86, 101]. Comparatively, the response
975 of oligodendrocyte lineage cells to ischemic stroke has been less extensively
976 interrogated. Moreover, the phenotypic heterogeneity within each neuroglial
977 subpopulation and their molecular cross talk upon ischemic injury are insufficiently
978 understood, impeding a holistic perspective on the pathobiology of ischemic stroke.
979 Here we addressed these challenges by generating a large scale single cell resolution
980 transcriptomic dataset of the mammalian brain's acute response to ischemic stroke.

981 Overall, neuroglial clusters emerged as the most transcriptionally perturbed cell
982 populations within our dataset. Within the oligodendrocyte lineage we detected two
983 transcriptional cell states which were almost uniquely detected within infarcted
984 hemispheres. In line with previous observations [14, 45], we found proliferating OPCs
985 at the perilesional zone of the infarcted hemisphere. However, beyond cell cycle
986 progression the transcriptome of these cells indicated the activation of multiple
987 survival, migration, ECM interaction and growth factor related pathways. This
988 observation suggests pleiotropic roles of OPCs during the brain's wound healing
989 response to ischemic injury. Indeed, although oligodendrogenesis and hence
990 contribution to myelination are historically the most prominently described features of
991 OPCs, they are increasingly realized to have more multifaceted roles, particularly in
992 response to injury [99].

993 The second infarction associated oligodendrocyte cell state occupied a unique branch
994 at the opposite edge of the oligodendrocyte developmental trajectory. Remarkably,
995 these oligodendrocytes also upregulated the immature oligodendrocyte marker BCAS-

996 1 and expressed several cell-cell and cell-ECM interaction associated genes, typically
997 enriched in immature oligodendrocytes. This observation might indicate an incomplete
998 ischemic injury induced reacquisition of immature oligodendrocytes features in a
999 subset of mature oligodendrocytes, a speculation necessitating further investigation.
1000 Interestingly, we did not detect a clear myelination associated gene signature within
1001 these cells. On the contrary, several myelin genes (e.g. *Mobp*, *Mbp*) were subtly
1002 downregulated and the inferred activity of several myelination and differentiation
1003 associated TFs was decreased in these cells, as compared to homeostatic mature
1004 oligodendrocytes. This observation suggests either that these oligodendrocytes are
1005 not yet fully devoted to remyelination at this early post ischemic time point, or that they
1006 assume alternative functions during the ischemic wound healing progression. As we
1007 have only sampled brain tissue 48h post injury, our study is not suited to answer this
1008 question conclusively, inviting further investigations. Importantly, recent research has
1009 demonstrated a limited and aberrant remyelination capacity of oligodendrocytes
1010 surviving demyelination compared to newly formed, progenitor derived
1011 oligodendrocytes [70]. We therefore propose that future work elucidating the potentially
1012 divergent fates and remyelination capacities of OPCs and *a priori* mature
1013 oligodendrocytes, following ischemic injury will be crucial.

1014 The transcriptional overlap between the stroke associated oligodendrocyte lineage
1015 clusters within our dataset with previously described DAO signatures was overall
1016 limited, possibly indicating a fine tuned ischemia specific injury response. However,
1017 the DAO signature reported in Pandey et al. (2022) are derived from rodent models of
1018 neurodegeneration and de-/remyelination with disease courses ranging from multiple
1019 weeks to months [73]. Thus, it is possible that the 48h post injury sampling time point
1020 in our study was too early to observe the emergence of a more prominent DAO-like
1021 signature. Moreover, other diverging neurodegeneration associated DAO signatures
1022 have been reported and contain further partial overlaps to the stroke associated
1023 oligodendrocyte lineage cells in our dataset [48], for example regarding the
1024 upregulation of interleukin 33 (*Il33*). However, within our sample *Il33* was not
1025 upregulated in mature stroke associated oligodendrocyte but robustly delineated
1026 stroke associated OPC in our snRNAseq dataset, as well as *in situ*. Importantly, *Il33*
1027 was shown to exert neuroprotective effects during cerebral ischemia via ST2 mediated
1028 immunomodulatory signalling onto microglia and regulatory T cells [60, 100].
1029 Moreover, *Il33* was implicated in the physiological progression of OPCs to mature

1030 oligodendrocytes [92]. The upregulation of *Il33* in OPCs during cerebral ischemia might
1031 hence be involved in multiple neuroprotective pathways.

1032 The majority of reactive astrocytes within our dataset upregulated gene sets
1033 associated to BBB maintenance, migration, cell-cell and ECM interaction, in line with
1034 previous work [13, 80]. This transcriptional profile corresponds well to the canonical
1035 roles of astrocytes in ECM scaffold formation and spatial containment of the neurotoxic
1036 core lesions microenvironment following CNS injury [86]. As expected, the reactive
1037 astrocyte signatures within our dataset overlapped with the canonical ischemia
1038 associated A2-signature, but not with the inflammation induced A1-signature [59, 103].
1039 Interestingly, the stroke reactive astrocyte transcriptomes in our dataset overlapped
1040 partially with MS “reactive/stressed astrocytes” [1] and neurodegeneration associated
1041 DAA signatures [36], highlighting common astrocyte responses to diverse neuronal
1042 injuries. Notably, we identified a small, predominantly severe infarction derived, subset
1043 of reactive astrocytes (AC_5), characterized by an upregulation of primary cilium
1044 associated genes. Intriguingly, a similar enrichment of primary cilium associated genes
1045 was previously identified in reactive astrocyte subsets in MS and Parkinson’s disease
1046 [1, 78]. Furthermore, Wei et al. have recently characterized a population of astrocyte-
1047 ependymal cells in spinal cord tissue which expanded after acute injury [97]. This
1048 population shared several transcriptional similarities with the reactive AC_5 subcluster
1049 in our dataset such as the upregulation of *Rfx3* and *Dnah* encoding genes and
1050 increased *Foxj1* TF activity. The precise origin and function of cilia gene enriched or
1051 astrocyte-ependymal cell states in response to CNS injuries are still largely unknown.
1052 Astrocytes and ependymal cells are developmentally closely related and they form a
1053 common transcriptional taxon [104]. Limited by the low number of captured AC_5
1054 nuclei and the single sampling time point in our study, we can thus far not conclude
1055 whether the expansion of the AC_5 cluster upon MCAO was caused by the acquisition
1056 of ependymal cell features by astrocytes, upregulation of reactive astrocytes genes in
1057 ependymal cells, or both. Further studies will be necessary to unveil the elusive role of
1058 these cells in ischemic stroke and other neuropathologies.

1059 Under physiological conditions astrocytes are crucially involved in the regulation of ion
1060 and neurotransmitter signalling, as well as synapse assembly and maintenance [96].
1061 Our findings indicate a possible loss of these homeostatic functions in stroke reactive
1062 astrocytes. Likewise, oligodendrocyte lineage cells are increasingly recognized to be

1063 coupled to neuronal neurotransmitter signalling via bidirectional cross talk, at OPC and
1064 axo-myelinic synapses [68, 99]. Interestingly, similarly to astrocytes, multiple
1065 neurotransmitter receptors, ion channels and ion channel interacting proteins were
1066 downregulated in oligodendrocyte lineage cells upon cerebral ischemia. Some of these
1067 genes were also downregulated subtly in the hemisphere contralateral to infarction.
1068 Further studies will be necessary to assess whether these changes functionally relate
1069 to possible disruptions of homeostatic oligodendroglia-neuronal crosstalk.

1070 While comparing the cerebral ischemia induced transcriptional perturbations in
1071 oligodendrocyte lineage cells and astrocytes we noticed further, more prominent
1072 similarities between infarction restricted oligodendrocyte lineage and astrocyte
1073 populations. Similar to reactive astrocytes, infarction restricted OPCs upregulated
1074 migration, cell-cell and ECM-interaction genes (e.g. *Met*, *Cdh2*, *Tnc*, *Adamts1*,
1075 *Adamts9*, *Vim*, *Cd44*) and colocalized with reactive astrocytes at the perilesional zone.
1076 It is thus possible that the perilesional microenvironment instructs a shared phenotype
1077 onto these populations. The partial acquisition of reactive astrocyte associated genes
1078 in oligodendrocytes after injury has also been noted in previous studies. Importantly,
1079 Kirdajova et al. have documented the emergence of a stroke specific, transient,
1080 proliferating “Astrocyte-like NG2 glia” population seven days after focal cerebral
1081 ischemia and speculated that this population might contribute to early glial scar
1082 formation [50]. Although, a subset of OPCs progresses to myelinating
1083 oligodendrocytes following ischemic stroke particularly in young animals [45], a
1084 substantial amount of OPCs remains undifferentiated for up to eight weeks post injury,
1085 suggesting potential alternative cell fates [14].

1086 More recently it was also shown that *bona fide* mature oligodendrocytes can
1087 dedifferentiate via a hybrid “AO cell” state into astrocytes *in vivo*, in the days to weeks
1088 following traumatic and ischemic brain injury [7]. This phenotypic switch was causally
1089 linked to IL6 signalling. Interestingly, the infarction enriched mature oligodendrocytes
1090 in our dataset would be primed to respond to this cytokine due to the prominent
1091 upregulation of canonical downstream targets of IL6, such as *Il6st* and *Stat3*. However,
1092 the transcriptional similarities between reactive OPCs, oligodendrocytes and astrocyte
1093 cluster within our datasets do not necessarily indicate that they harbour the progeny of
1094 hybrid cell states. Moreover, overlaps in gene and TF signatures do not unequivocally
1095 dictate shared functions during neural regeneration. For example, traumatic injury

1096 induced STAT3 activation in astrocytes is involved in GFAP upregulation, induction of
1097 cellular hypertrophy and glial scar formation [40], while in oligodendrocytes STAT3
1098 signalling was implicated in maturation and remyelination after focal demyelination
1099 [91]. Further studies will be necessary to decipher the precise functional consequences
1100 of the herein described gene expressional changes in oligodendroglia and astrocytes.

1101 The recruitment of reactive neuroglia and immune cells to the injury site is a crucial
1102 step during the acute ischemic injury response [23]. Our data indicate that myeloid
1103 cells might be involved in orchestrating this process. We confirmed the emergence of
1104 SAMC specifically within infarcted brain tissue. The sparsity of myeloid cells within non-
1105 lesioned brain tissue is a previously elaborated [15] limitation of our nuclei isolation
1106 approach and impeded a direct comparison of SAMC to homeostatic microglia within
1107 this study, which has already been conducted elsewhere [10]. Although the herein
1108 used method of nuclei isolation is prone to exclude immune cells, they were robustly
1109 captured within infarcted tissue, highlighting their drastically increased abundance in
1110 the infarct lesion. The clearance of lipid-rich tissue debris has been established as a
1111 primary function of SAMC [10], although alternative functions, such as the reduction of
1112 ROS stress, have been described [49]. Here we observed that myeloid cells expressing
1113 the canonical SAMC marker osteopontin accumulate in close proximity to reactive
1114 astrocytes and proliferating OPCs which robustly expressed the osteopontin receptor
1115 CD44 in the perilesional zone. Furthermore, we were able to show that osteopontin
1116 increased the migratory capacity of OPCs *in vitro*. Indeed, osteopontin is a well-
1117 established inductor of cellular migration in numerous cell types and has been
1118 implicated to act as a chemotactic cue via CD44 mediated signalling [56, 95]. In
1119 addition, CD44 was shown to be indispensable for the migration of transplanted rat
1120 OPC-like CG4 cells towards focal demyelinated lesions [74], and macrophage derived
1121 osteopontin was shown to induce the extension of astrocyte processes towards the
1122 infarct perilesional zone following focal cerebral ischemia [33]. The accumulation of
1123 CD44 positive astrocytes and immune cells in the peri-infarct zone was previously
1124 shown and associated to a homing towards the CD44 ligand hyaluronic acid, which
1125 also accumulates at the peri-infarct border [2, 3, 83]. Importantly, our CCC analysis
1126 inferred that CD44 is indeed targeted by multiple ligands in infarcted tissue specifically.
1127 Likewise, osteopontin was predicted to signal onto multiple other receptors, such as
1128 integrins which was previously also associated to increased migration [106]. As the
1129 recruitment of neuroglia and immune cells to the site of injury is a prerequisite for

1130 further regenerative mechanisms, it is highly plausible that multiple redundant
1131 mechanisms have evolved to achieve this. Moreover, the role of osteopontin in
1132 ischemic stroke likely exceeds the regulation of cellular migration, although its precise
1133 contribution to post ischemic regeneration is still controversial. For example,
1134 osteopontin has been shown to acutely aggravate ischemia-induced BBB disruption
1135 [90], but augment white matter integrity via immunomodulatory mechanisms, in the
1136 subacute to chronic stages of stroke recovery [87]. A further complicating factor is the
1137 age dependency of many molecular cross talk events during the response to cerebral
1138 ischemia. For example, osteopontin to CD44 signaling was largely restricted to young
1139 animals in a previous study [45]. The fact that our results are based on a homogenous
1140 cohort of young, male rats is an evident limitation that has to be taken into account
1141 when extrapolating translational considerations from this dataset.

1142 In summary, our study captured the emergence of cell type and cerebral infarction
1143 specific transcriptional signatures in neuroglia. Although, reactive oligodendrocyte
1144 lineage cells and astrocytes exhibited distinct responses their transcriptional
1145 signatures overlapped substantially, indicating a shared molecular ischemia response
1146 repertoire and possibly shared functions during regeneration. Moreover, we uncovered
1147 a shared immuno-glial molecular cross talk, which implicated myeloid cells as
1148 contributors to OPC and reactive astrocyte recruitment to the injury site via the
1149 osteopontin CD44 signaling axis. Beyond the diverse transcriptional response patterns
1150 highlighted in our analysis, the large scale dataset generated within this study will
1151 provide an instrumental resource for the interrogation of acute cell type specific
1152 responses to ischemic stroke. We propose, that this approach will contribute to
1153 untangle the complex mechanisms governing post ischemic neural regeneration,
1154 ultimately aiding in the discovery of novel treatment strategies to alleviate the
1155 devastating consequences of ischemic stroke.

1156

1157

1158

1159

1160

1161

1162




Figure 1.

1193 **Figure 1. snRNAseq reveals differential cell cluster abundance and cluster**
1194 **specific transcriptional perturbations 48h after ischemic stroke. (a)** Illustration of
1195 study design, depicting brain regions sampled for snRNAseq, from n=4 Sham control
1196 rats and n=7 MCAO rats. MRI images of brain tissue from Sham operated, mMCAO
1197 and sMCAO rats are presented, ischemic lesions are highlighted in red. **(b)** UMAP plot
1198 depicting 68616 nuclei annotated to 29 major cell clusters in the overall integrated
1199 dataset. Cell cluster abbreviations: AC: astrocyte cluster, CHOL_IN: cholinergic
1200 interneurons, EP_M_C: ependymal and mural cell cluster, GABA_Amb: Ambiguous
1201 GABAergic neuronal cluster, GABA_IN_Adarb2+, GABA_IN_Adarb2-: GABAergic
1202 interneurons, *Adarb2* positive/negative, respectively, GABA_MSN: GABAergic
1203 medium spiny neurons, GLU_Satb2+, GLU_Satb2-: Glutamatergic neurons, *Satb2*
1204 positive/negative, respectively, OLIGO_1: immature oligodendrocyte lineage cluster,
1205 OLIGO_2: myelinating and mature oligodendrocyte lineage cluster. **(c)** Dotplots
1206 depicting curated marker genes for all major cell clusters. The dendrogram on top of
1207 the left dotplot represents overarching taxons of identified major cell clusters. The
1208 dotplot in the middle depicts curated cluster markers of glutamatergic neurons. Colored
1209 bars next to the gene names denote established associations to cortical layers.
1210 Representative corresponding RNA in situ hybridization (ISH) results are depicted next
1211 to the colored bars. All RNA ISH studies were taken from Allen Brain Atlas database
1212 [57], and are referenced in detail in Suppl.Tab.3. Abbreviations: L = layer, CLA =
1213 claustrum, ec = external capsule, LSr = lateral septal nucleus, PIR = piriform cortex.
1214 Dotplot on the right shows marker gene expression in cholinergic and GABAergic
1215 neurons. **(d)** Stacked bar plot depicting the relative abundance of each cell cluster
1216 within each sample. **(e)** Top: Nuclei distribution coloured by treatment group. Bottom:
1217 Gene module score derived from the stroke-associated myeloid cell (SAMC) gene set
1218 [10]. **(f)** Strip plots depicting distribution of DEGs derived from MCAO ipsi vs Sham and
1219 MCAO ipsi vs MCAO contra comparisons, for all major cell clusters.

1220

1221

1222

1223

1224




Figure 2.

1249 **Figure 2. Emergence of transcriptionally distinct OPCs and mature**
1250 **oligodendrocytes within infarcted brain tissue. (a)** Subclustering of
1251 oligodendrocyte lineage clusters. Top left: UMAP plot depicting 10240 nuclei annotated
1252 to 10 subclusters, bottom left: stacked bar plot depicting the relative abundance of each
1253 subcluster within each group, bottom right: Nuclei distribution coloured by treatment
1254 group, right panel: dotplot depicting curated sub cluster markers. Subcluster
1255 abbreviations: OPC: oligodendrocyte precursor cell, COP: committed oligodendrocyte
1256 precursor, NFOLIGO: newly formed oligodendrocyte, MFOLIGO: myelin forming
1257 oligodendrocyte, MOLIGO: mature oligodendrocyte, MC_OLIGO: myeloid cell
1258 oligodendrocyte mixed cluster. **(b)** Top: Projection of Monocle3 generated pseudotime
1259 trajectory onto subcluster UMAP plot, with subcluster OPC_0 as root. Feature Plots
1260 depicting S-phase (middle) and G2/M-phase (bottom) gene module scores. **(c)**
1261 Volcano plots depicting DEGs derived from the comparison of clusters OPC_1 to
1262 OPC_0 (top) and MOLIGO_1 to MOLIGO_2 (bottom). **(d)** Heatmap depicting the
1263 average scaled gene expression of curated DEGs, split by subcluster and treatment
1264 group. Functional annotations are given on the left side of the gene names. **(e)** Top:
1265 Clustered heatmap depicting aggregate gene expressions of Monocle3 derived co-
1266 regulated gene modules. Modules associated to OPC_1 and MOLIGO_1 are
1267 highlighted in light and dark red, respectively. Bottom: The average aggregate
1268 expression of the OPC_1 and MOLIGO_1 associated modules is plotted along the
1269 pseudo time trajectory. The Top 25 module defining genes, as sorted by descending
1270 Moran's I, are depicted in boxes on the right side of the respective gene module feature
1271 plots. **(f)** Heatmap depicting the top 100 most variable decoupleR derived transcription
1272 factor activities, within the oligodendrocyte lineage sub clustering analysis, split by sub
1273 cluster and treatment group.

1274


1275

1276

1277

1278

1279



1303 **Figure 3.**

1304

1305 **Figure 3. Proliferating OPCs accumulate in the perilesional zone 48 h after**
1306 **ischemic stroke and express VIM and IL33. (a)** Overview of a representative coronal
1307 brain section 48 h post MCAO, stained for NG2, VIM and Ki67. Grey matter ROIs (GM)
1308 are highlighted in violet, white matter ROIs (WM) in lime green, lower right inset depicts
1309 a corresponding T2 weighted MRI image from the same animal. Bar = 2 mm **(b)**
1310 Representative images from GM and WM ROIs of Sham, MCAO contra and MCAO
1311 ipsi sections, split by antigen. Ki67 = magenta, NG2 = Cyan, VIM = yellow, DAPI
1312 (nuclei) = blue, bars = 50 μ m. White arrowheads point to triple positive cells. **(c)** Cell
1313 counts within GM and WM respectively are presented as box plots for NG2⁺/VIM⁺/Ki67⁺
1314 triple positive cells. Cell counts for NG2⁺/VIM⁺/Ki67⁺, NG2⁺/VIM⁻/Ki67⁺,
1315 NG2⁺/VIM⁺/Ki67⁻, NG2⁺/VIM⁻/Ki67⁻ are also jointly shown as colored stacked bar plot.
1316 **(d)** Representative coronal overview, 48 h post MCAO, stained for NG2, IL33, Ki67.
1317 GM ROIs in violet, WM ROIs in lime green, lower right inset shows a corresponding
1318 MRI image from the same animal. Bar = 2 mm **(e)** Representative images from GM
1319 and WM ROIs derived from Sham, MCAOcontra and MCAOipsi groups, split by
1320 antigen. Ki67 = magenta, NG2 = Cyan, IL33 = yellow, DAPI (nuclei) = blue, bars = 50
1321 μ m White arrowheads point to triple positive cells. **(f)** Cell counts within GM and WM
1322 are presented as box plots for NG2⁺/IL33⁺/Ki67⁺ triple positive cells. Cell counts for
1323 NG2⁺/IL33⁺/Ki67⁺, NG2⁺/IL33⁻/Ki67⁺, NG2⁺/IL33⁺/Ki67⁻, NG2⁺/IL33⁻/Ki67⁻ are also
1324 jointly shown as colored stacked bar plot. Data derived from n = 4-5 animals per group,
1325 p values derived from Kruskal-Wallis-H-Tests, followed by Dunn's post hoc
1326 comparisons.

1327

1328

1329

1330

1331

1332

1333

1334

1335




Figure 4.

1352

1353

1354

1355

1356

1357

1358

1359

1360 **Figure 4. Transcriptional heterogeneity of reactive astrocytes within infarcted**
1361 **brain tissue. (a)** Subclustering analysis of astrocytes. Top left: UMAP plot depicting
1362 1233 nuclei annotated to 5 subclusters, bottom left: stacked bar plots depicting the
1363 absolute and relative abundance of each subcluster within each group, bottom right:
1364 Nuclei distribution coloured by group, right panel: Dotplot depicting curated
1365 homeostatic and reactive astrocyte marker genes. **(b)** Volcano plots depicting DEG
1366 derived from the comparison of the reactive astrocyte subclusters AC_3 (left), AC_4
1367 (middle) and AC_5 (right) to the homeostatic astrocyte subclusters (AC_1 and AC_2,
1368 pooled). **(c-f)** Heatmaps depicting the average scaled gene expression of curated
1369 upregulated DEGs, derived from the comparison of AC_3 and AC_4 **(c)** and AC_5 **(d)**
1370 to homeostatic astrocytes, as well as DEGs downregulated in reactive astrocytes **(e)**,
1371 split by subcluster and group. **(f)** Clustered heatmap depicting the top 50 most variable
1372 decoupleR derived transcription factor activities, within the astrocyte lineage
1373 subclustering analysis, split by subcluster and treatment group.

1374

1375

1376

1377

1378

1379

1380

1381

1382


1383

1384

1385

1386

1387



1411 **Figure 5.**

1412 **Figure 5. Reactive astrocytes and proliferating OPCs are CD44 positive and**
1413 **abundant in the perilesional zone 48 h after ischemic stroke. (a)** Overview of a
1414 representative coronal brain section 48 h post MCAO, stained for GFAP, CD44 and
1415 VIM. Grey matter ROIs (GM) are highlighted in violet, white matter ROIs (WM) in lime
1416 green, lower right inset depicts a corresponding T2 weighted MRI image from the same
1417 animal. Bar = 2mm **(b)** Representative images taken from GM and WM ROIs of Sham,
1418 MCAO contra and MCAO ipsi sections, split by antigen. VIM = magenta, GFAP = Cyan,
1419 CD44 = yellow, all overlaid with DAPI (nuclei) = blue. Bars = 50 μ m. White arrowheads
1420 point to NG2+/CD44+/Ki67+ triple positive cells. **(c)** Cell counts within GM and WM are
1421 presented as box plots for GFAP+/CD44+/VIM+ triple positive cells. Cell counts for
1422 GFAP+/CD44+/VIM+, GFAP+/CD44-/VIM+, GFAP+/CD44+/VIM-, GFAP+/CD44-/VIM- are
1423 also jointly shown as colored stacked bar plot. **(d)** Representative coronal overview,
1424 48 h post MCAO, stained for NG2, CD44, Ki67. GM ROIs in violet, WM ROIs in lime
1425 green, lower right inset shows corresponding MRI image from the same animal. Bar =
1426 2mm **(e)** Representative images from GM and WM ROIs taken from Sham, MCAO
1427 contra and MCAO ipsi groups, split by antigen. Ki67 = magenta, NG2 = Cyan, CD44 =
1428 yellow. Bars = 50 μ m. White arrowheads point to NG2+/CD44+/Ki67+ triple positive
1429 cells. **(f)** Cell counts within GM and WM respectively are presented as box plots for
1430 NG2+/CD44+/Ki67+. Cell counts for NG2+/CD44+/Ki67+, NG2+/CD44-/Ki67+,
1431 NG2+/CD44+/Ki67-, NG2+/CD44-/Ki67- are also jointly shown as colored stacked bar
1432 plot. Data derived from n = 4-5 animals per group, p values derived from Kruskal-
1433 Wallis-H-Tests, followed by Dunn's post hoc comparisons.

1434

1435

1436

1437


1438

1439

1440

1441

1442



1454 **Figure 6.**

1455

1456

1457

1458

1459

1460

1461

1462

1463

1464

1465

1466

1467 **Figure 6. Osteopontin positive myeloid cells accumulate in the perilesional zone**
1468 **in close proximity to CD44 positive cells 48 h after ischemic stroke. (a)** Overview
1469 of a representative coronal brain section 48 h post MCAO, stained for Iba1, CD44 and
1470 OPN. Grey matter ROIs (GM) are highlighted in violet, white matter ROIs (WM) in lime
1471 green, lower right inset depicts a corresponding T2 weighted MRI image from the same
1472 animal. Bar = 2 mm. **(b)** Representative images from GM and WM ROIs of Sham,
1473 MCAOcontra and MCAO ipsi sections, split by antigen. OPN = magenta, Iba1 = cyan,
1474 CD44 = yellow. Bar = 50 μ m. **(c)** Cell counts within GM and WM are presented as box
1475 plots for Iba1⁺/OPN⁺ double positive cells, cell counts for Iba1⁺/CD44⁺/OPN⁺,
1476 Iba1⁺/CD44⁻/OPN⁺, Iba1⁺/CD44⁺/OPN⁻, Iba1⁺/CD44⁻/OPN⁻ are jointly shown as colored
1477 stacked bar plot. Data derived from n = 4-5 animals per group, p values derived from
1478 Kruskal-Wallis-H-Tests, followed by Dunn's post hoc comparisons.

1479

1480

1481

1482

1483

1484

1485

1486

1487

1488

1489


1490

1491

1492

1493

1494



1510 **Figure 7.**

1511

1512

1513

1514

1515

1516

1517

1518

1519 **Figure 7. Osteopontin induces OPC migration but not proliferation *in vitro*.** (a) *In*
1520 *vitro* cell migration assay. Cells were seeded in 2 well culture inserts, creating defined
1521 500 μm gaps. NG2 positive cells which migrated into the 500 μm gap were quantified
1522 after 48 h of treatment. Representative images of OPC cell cultures 48 h after
1523 incubation without (upper panel: untreated control = UC), or with 1 $\mu\text{g}/\text{ml}$ OPN (lower
1524 panel), stained for DAPI (nuclei) = blue, Ki67 = magenta and NG2 = cyan, split by
1525 channel. Scale bars denote 500 μm gaps. Box plots on the right show the number of
1526 NG2 positive cells, which migrated into 500 μm gaps, for each condition, p-values
1527 derived from unpaired student's t-test ($t=3,097$, $df=14$, $n=8$ replicates per group, from
1528 2 independent experiments). In $n = 4$ replicates per group from 2 independent
1529 experiments Ki67 was visualized. Lower Boxplot depicts the percentages of Ki67⁺ cells
1530 within the 500 μm gap, for each condition, p values derived from unpaired student's t-
1531 test ($t=0,7150$, $df=6$). (b) BrdU incorporation assay. BrdU incorporation was visualized
1532 24h after incubation without (UC) (upper panel) or with 1 $\mu\text{g}/\text{ml}$ OPN (lower panel).
1533 Representative 20x magnification images are shown, stained for DAPI (Nuclei) = blue,
1534 BrdU = magenta and NG2 = cyan, split by channel. Scale bars = 100 μm . Boxplot
1535 depicts the percentages of BrdU⁺ cells, for each group, p values derived from unpaired
1536 student's t-test ($t=0,8219$, $df=6$, $n=4$ replicates per group, from 1 independent
1537 experiment).

1538

1539

1540

1541

1542

1543

1544

1545

1546

1547

1548

1549

1550

1551 References

- 1552 1 Absinta M, Maric D, Gharagozloo M, Garton T, Smith MD, Jin J, Fitzgerald KC, Song A, Liu P,
1553 Lin JPet al (2021) A lymphocyte-microglia-astrocyte axis in chronic active multiple sclerosis.
1554 Nature 597: 709-714 Doi 10.1038/s41586-021-03892-7
- 1555 2 Al'Qteishat A, Gaffney J, Krupinski J, Rubio F, West D, Kumar S, Kumar P, Mitsios N, Slevin M
1556 (2006) Changes in hyaluronan production and metabolism following ischaemic stroke in man.
1557 Brain 129: 2158-2176 Doi 10.1093/brain/awl139
- 1558 3 Al Qteishat A, Gaffney JJ, Krupinski J, Slevin M (2006) Hyaluronan expression following
1559 middle cerebral artery occlusion in the rat. Neuroreport 17: 1111-1114 Doi
1560 10.1097/01.wnr.0000227986.69680.20
- 1561 4 Ali MF, Latimer AJ, Wang Y, Hogenmiller L, Fontenas L, Isabella AJ, Moens CB, Yu G, Kucenas S
1562 (2021) Met is required for oligodendrocyte progenitor cell migration in Danio rerio. G3
1563 (Bethesda) 11: Doi 10.1093/g3journal/jkab265
- 1564 5 Anfray A, Brodin C, Drieu A, Potzeha F, Dalarun B, Agin V, Vivien D, Orset C (2021) Single- and
1565 two- chain tissue type plasminogen activator treatments differentially influence cerebral
1566 recovery after stroke. Exp Neurol 338: 113606 Doi 10.1016/j.expneurol.2021.113606
- 1567 6 Badia IMP, Vélez Santiago J, Braunger J, Geiss C, Dimitrov D, Müller-Dott S, Taus P, Dugourd
1568 A, Holland CH, Ramirez Flores ROet al (2022) decoupleR: ensemble of computational
1569 methods to infer biological activities from omics data. Bioinform Adv 2: vbac016 Doi
1570 10.1093/bioadv/vbac016
- 1571 7 Bai X, Zhao N, Koupourtidou C, Fang LP, Schwarz V, Caudal LC, Zhao R, Hirrlinger J, Walz W,
1572 Bian Set al (2023) In the mouse cortex, oligodendrocytes regain a plastic capacity,
1573 transforming into astrocytes after acute injury. Dev Cell 58: 1153-1169.e1155 Doi
1574 10.1016/j.devcel.2023.04.016
- 1575 8 Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, McQuaid S,
1576 Gray RT, Murray LJ, Coleman HGet al (2017) QuPath: Open source software for digital
1577 pathology image analysis. Sci Rep 7: 16878 Doi 10.1038/s41598-017-17204-5
- 1578 9 Bernhardt J, Hayward KS, Kwakkel G, Ward NS, Wolf SL, Borschmann K, Krakauer JW, Boyd
1579 LA, Carmichael ST, Corbett Det al (2017) Agreed definitions and a shared vision for new
1580 standards in stroke recovery research: The Stroke Recovery and Rehabilitation Roundtable
1581 taskforce. Int J Stroke 12: 444-450 Doi 10.1177/1747493017711816
- 1582 10 Beuker C, Schafflick D, Strecker JK, Heming M, Li X, Wolbert J, Schmidt-Pogoda A, Thomas C,
1583 Kuhlmann T, Aranda-Pardos Iet al (2022) Stroke induces disease-specific myeloid cells in the
1584 brain parenchyma and pia. Nat Commun 13: 945 Doi 10.1038/s41467-022-28593-1
- 1585 11 Blanco-Carmona E (2022) Generating publication ready visualizations for Single Cell
1586 transcriptomics using SCpubr. bioRxiv: 2022.2002.2028.482303 Doi
1587 10.1101/2022.02.28.482303
- 1588 12 Blighe K, Rana S, Lewis M (2019) EnhancedVolcano: Publication-ready volcano plots with
1589 enhanced colouring and labeling. R package version 1:
- 1590 13 Boghdadi AG, Spurrier J, Teo L, Li M, Skarica M, Cao B, Kwan WC, Merson TD, Nilsson SK,
1591 Sestan Net al (2021) NogoA-expressing astrocytes limit peripheral macrophage infiltration
1592 after ischemic brain injury in primates. Nat Commun 12: 6906 Doi 10.1038/s41467-021-
1593 27245-0
- 1594 14 Bonfanti E, Gelosa P, Fumagalli M, Dimou L, Viganò F, Tremoli E, Cimino M, Sironi L,
1595 Abbracchio MP (2017) The role of oligodendrocyte precursor cells expressing the GPR17
1596 receptor in brain remodeling after stroke. Cell Death Dis 8: e2871 Doi
1597 10.1038/cddis.2017.256
- 1598 15 Bormann D, Copic D, Klas K, Direder M, Riedl CJ, Testa G, Kühtreiber H, Poreba E, Hametner
1599 S, Golabi Bet al (2023) Exploring the heterogeneous transcriptional response of the CNS to
1600 systemic LPS and Poly(I:C). Neurobiol Dis 188: 106339 Doi 10.1016/j.nbd.2023.106339
- 1601 16 Buizza C, Enström A, Carlsson R, Paul G (2023) The Transcriptional Landscape of Pericytes in
1602 Acute Ischemic Stroke. Transl Stroke Res: Doi 10.1007/s12975-023-01169-x

- 1603 17 Campbell BCV, De Silva DA, Macleod MR, Coutts SB, Schwamm LH, Davis SM, Donnan GA
1604 (2019) Ischaemic stroke. *Nat Rev Dis Primers* 5: 70 Doi 10.1038/s41572-019-0118-8
- 1605 18 Cao J, Spielmann M, Qiu X, Huang X, Ibrahim DM, Hill AJ, Zhang F, Mundlos S, Christiansen L,
1606 Steemers FJ et al (2019) The single-cell transcriptional landscape of mammalian
1607 organogenesis. *Nature* 566: 496-502 Doi 10.1038/s41586-019-0969-x
- 1608 19 Carulli D, de Winter F, Verhaagen J (2021) Semaphorins in Adult Nervous System Plasticity
1609 and Disease. *Front Synaptic Neurosci* 13: 672891 Doi 10.3389/fnsyn.2021.672891
- 1610 20 Cassidy JM, Cramer SC (2017) Spontaneous and Therapeutic-Induced Mechanisms of
1611 Functional Recovery After Stroke. *Transl Stroke Res* 8: 33-46 Doi 10.1007/s12975-016-0467-5
- 1612 21 Choudhary S, Satija R (2022) Comparison and evaluation of statistical error models for
1613 scRNA-seq. *Genome Biol* 23: 27 Doi 10.1186/s13059-021-02584-9
- 1614 22 Conway JR, Lex A, Gehlenborg N (2017) UpSetR: an R package for the visualization of
1615 intersecting sets and their properties. *Bioinformatics* 33: 2938-2940 Doi
1616 10.1093/bioinformatics/btx364
- 1617 23 Cregg JM, DePaul MA, Filous AR, Lang BT, Tran A, Silver J (2014) Functional regeneration
1618 beyond the glial scar. *Exp Neurol* 253: 197-207 Doi 10.1016/j.expneurol.2013.12.024
- 1619 24 Dai J, Bercury KK, Ahrendsen JT, Macklin WB (2015) Olig1 function is required for
1620 oligodendrocyte differentiation in the mouse brain. *J Neurosci* 35: 4386-4402 Doi
1621 10.1523/jneurosci.4962-14.2015
- 1622 25 Daniele SG, Trummer G, Hossmann KA, Vrselja Z, Benk C, Gobeske KT, Damjanovic D,
1623 Andrijevic D, Pooth JS, Dellal Det al (2021) Brain vulnerability and viability after ischaemia.
1624 *Nat Rev Neurosci* 22: 553-572 Doi 10.1038/s41583-021-00488-y
- 1625 26 Dimitrov D, Türei D, Garrido-Rodriguez M, Burmedi PL, Nagai JS, Boys C, Ramirez Flores RO,
1626 Kim H, Szalai B, Costa I Get al (2022) Comparison of methods and resources for cell-cell
1627 communication inference from single-cell RNA-Seq data. *Nat Commun* 13: 3224 Doi
1628 10.1038/s41467-022-30755-0
- 1629 27 Dzwonek J, Wilczynski GM (2015) CD44: molecular interactions, signaling and functions in the
1630 nervous system. *Front Cell Neurosci* 9: 175 Doi 10.3389/fncel.2015.00175
- 1631 28 Fan J, Li X, Yu X, Liu Z, Jiang Y, Fang Y, Zong M, Suo C, Man Q, Xiong L (2023) Global Burden,
1632 Risk Factor Analysis, and Prediction Study of Ischemic Stroke, 1990-2030. *Neurology* 101:
1633 e137-e150 Doi 10.1212/wnl.0000000000207387
- 1634 29 Fard MK, van der Meer F, Sánchez P, Cantuti-Castelvetri L, Mandad S, Jäkel S, Fornasiero EF,
1635 Schmitt S, Ehrlich M, Starost Let al (2017) BCAS1 expression defines a population of early
1636 myelinating oligodendrocytes in multiple sclerosis lesions. *Sci Transl Med* 9: Doi
1637 10.1126/scitranslmed.aam7816
- 1638 30 Finak G, McDavid A, Yajima M, Deng J, Gersuk V, Shalek AK, Slichter CK, Miller HW, McElrath
1639 MJ, Prlic Met al (2015) MAST: a flexible statistical framework for assessing transcriptional
1640 changes and characterizing heterogeneity in single-cell RNA sequencing data. *Genome Biol*
1641 16: 278 Doi 10.1186/s13059-015-0844-5
- 1642 31 Fulda S, Gorman AM, Hori O, Samali A (2010) Cellular stress responses: cell survival and cell
1643 death. *Int J Cell Biol* 2010: 214074 Doi 10.1155/2010/214074
- 1644 32 Gadani SP, Walsh JT, Smirnov I, Zheng J, Kipnis J (2015) The glia-derived alarmin IL-33
1645 orchestrates the immune response and promotes recovery following CNS injury. *Neuron* 85:
1646 703-709 Doi 10.1016/j.neuron.2015.01.013
- 1647 33 Gliem M, Krammes K, Liaw L, van Rooijen N, Hartung HP, Jander S (2015) Macrophage-
1648 derived osteopontin induces reactive astrocyte polarization and promotes re-establishment
1649 of the blood brain barrier after ischemic stroke. *Glia* 63: 2198-2207 Doi 10.1002/glia.22885
- 1650 34 Gu Z, Eils R, Schlesner M (2016) Complex heatmaps reveal patterns and correlations in
1651 multidimensional genomic data. *Bioinformatics* 32: 2847-2849 Doi
1652 10.1093/bioinformatics/btw313
- 1653 35 Guo K, Luo J, Feng D, Wu L, Wang X, Xia L, Tao K, Wu X, Cui W, He Yet al (2021) Single-Cell
1654 RNA Sequencing With Combined Use of Bulk RNA Sequencing to Reveal Cell Heterogeneity

- 1655 and Molecular Changes at Acute Stage of Ischemic Stroke in Mouse Cortex Penumbra Area.
1656 *Front Cell Dev Biol* 9: 624711 Doi 10.3389/fcell.2021.624711
- 1657 36 Habib N, McCabe C, Medina S, Varshavsky M, Kitsberg D, Dvir-Szternfeld R, Green G, Dionne
1658 D, Nguyen L, Marshall J et al (2020) Disease-associated astrocytes in Alzheimer's disease and
1659 aging. *Nat Neurosci* 23: 701-706 Doi 10.1038/s41593-020-0624-8
- 1660 37 Hafemeister C, Satija R (2019) Normalization and variance stabilization of single-cell RNA-seq
1661 data using regularized negative binomial regression. *Genome Biol* 20: 296 Doi
1662 10.1186/s13059-019-1874-1
- 1663 38 Hammond TR, Dufort C, Dissing-Olesen L, Giera S, Young A, Wysoker A, Walker AJ, Gergits F,
1664 Segel M, Nemesh J et al (2019) Single-Cell RNA Sequencing of Microglia throughout the
1665 Mouse Lifespan and in the Injured Brain Reveals Complex Cell-State Changes. *Immunity* 50:
1666 253-271.e256 Doi 10.1016/j.immuni.2018.11.004
- 1667 39 Hao Y, Hao S, Andersen-Nissen E, Mauck WM, 3rd, Zheng S, Butler A, Lee MJ, Wilk AJ, Darby
1668 C, Zager M et al (2021) Integrated analysis of multimodal single-cell data. *Cell* 184: 3573-
1669 3587.e3529 Doi 10.1016/j.cell.2021.04.048
- 1670 40 Herrmann JE, Imura T, Song B, Qi J, Ao Y, Nguyen TK, Korsak RA, Takeda K, Akira S, Sofroniew
1671 MV (2008) STAT3 is a critical regulator of astrogliosis and scar formation after spinal cord
1672 injury. *J Neurosci* 28: 7231-7243 Doi 10.1523/jneurosci.1709-08.2008
- 1673 41 Hu YH, Zhang Y, Jiang LQ, Wang S, Lei CQ, Sun MS, Shu HB, Liu Y (2015) WDFY1 mediates
1674 TLR3/4 signaling by recruiting TRIF. *EMBO Rep* 16: 447-455 Doi 10.15252/embr.201439637
- 1675 42 Huang JK, Jarjour AA, Nait Oumesmar B, Kerninon C, Williams A, Krezel W, Kagechika H,
1676 Bauer J, Zhao C, Baron-Van Evercooren A et al (2011) Retinoid X receptor gamma signaling
1677 accelerates CNS remyelination. *Nat Neurosci* 14: 45-53 Doi 10.1038/nn.2702
- 1678 43 Huang S, Ren C, Luo Y, Ding Y, Ji X, Li S (2023) New insights into the roles of oligodendrocytes
1679 regulation in ischemic stroke recovery. *Neurobiol Dis* 184: 106200 Doi
1680 10.1016/j.nbd.2023.106200
- 1681 44 Ignatenko O, Malinen S, Rybas S, Vihinen H, Nikkanen J, Kononov A, Jokitalo ES, Ince-Dunn G,
1682 Suomalainen A (2023) Mitochondrial dysfunction compromises ciliary homeostasis in
1683 astrocytes. *J Cell Biol* 222: Doi 10.1083/jcb.202203019
- 1684 45 Jin C, Shi Y, Shi L, Leak RK, Zhang W, Chen K, Ye Q, Hassan S, Lyu J, Hu X et al (2023)
1685 Leveraging single-cell RNA sequencing to unravel the impact of aging on stroke recovery
1686 mechanisms in mice. *Proc Natl Acad Sci U S A* 120: e2300012120 Doi
1687 10.1073/pnas.2300012120
- 1688 46 Kanda A, Noda K, Hirose I, Ishida S (2019) TGF- β -SNAIL axis induces Müller glial-mesenchymal
1689 transition in the pathogenesis of idiopathic epiretinal membrane. *Sci Rep* 9: 673 Doi
1690 10.1038/s41598-018-36917-9
- 1691 47 Kaneko N, Herranz-Pérez V, Otsuka T, Sano H, Ohno N, Omata T, Nguyen HB, Thai TQ, Nambu
1692 A, Kawaguchi Y et al (2018) New neurons use Slit-Robo signaling to migrate through the glial
1693 meshwork and approach a lesion for functional regeneration. *Sci Adv* 4: eaav0618 Doi
1694 10.1126/sciadv.aav0618
- 1695 48 Kenigsbuch M, Bost P, Halevi S, Chang Y, Chen S, Ma Q, Hajbi R, Schwikowski B, Bodenmiller
1696 B, Fu H et al (2022) A shared disease-associated oligodendrocyte signature among multiple
1697 CNS pathologies. *Nat Neurosci* 25: 876-886 Doi 10.1038/s41593-022-01104-7
- 1698 49 Kim S, Lee W, Jo H, Sonn SK, Jeong SJ, Seo S, Suh J, Jin J, Kweon HY, Kim T et al (2022) The
1699 antioxidant enzyme Peroxiredoxin-1 controls stroke-associated microglia against acute
1700 ischemic stroke. *Redox Biol* 54: 102347 Doi 10.1016/j.redox.2022.102347
- 1701 50 Kirdajova D, Valihrach L, Valny M, Kriska J, Krocianova D, Benesova S, Abaffy P, Zucha D,
1702 Klassen R, Kolenicova D et al (2021) Transient astrocyte-like NG2 glia subpopulation emerges
1703 solely following permanent brain ischemia. *Glia* 69: 2658-2681 Doi 10.1002/glia.24064
- 1704 51 Kolberg L, Raudvere U, Kuzmin I, Vilo J, Peterson H (2020) gprofiler2 -- an R package for gene
1705 list functional enrichment analysis and namespace conversion toolset g:Profiler. *F1000Res* 9:
1706 Doi 10.12688/f1000research.24956.2

- 1707 52 Kolde R (2012) Pheatmap: pretty heatmaps. R package version 1: 726
- 1708 53 Kolonko M, Greb-Markiewicz B (2019) bHLH-PAS Proteins: Their Structure and Intrinsic
1709 Disorder. *Int J Mol Sci* 20: Doi 10.3390/ijms20153653
- 1710 54 Krämer-Albers EM, White R (2011) From axon-glia signalling to myelination: the integrating
1711 role of oligodendroglial Fyn kinase. *Cell Mol Life Sci* 68: 2003-2012 Doi 10.1007/s00018-010-
1712 0616-z
- 1713 55 Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, Koplev S, Jenkins SL,
1714 Jagodnik KM, Lachmann A et al (2016) Enrichr: a comprehensive gene set enrichment analysis
1715 web server 2016 update. *Nucleic Acids Res* 44: W90-97 Doi 10.1093/nar/gkw377
- 1716 56 Lee MN, Song JH, Oh SH, Tham NT, Kim JW, Yang JW, Kim ES, Koh JT (2020) The primary
1717 cilium directs osteopontin-induced migration of mesenchymal stem cells by regulating CD44
1718 signaling and Cdc42 activation. *Stem Cell Res* 45: 101799 Doi 10.1016/j.scr.2020.101799
- 1719 57 Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, Bernard A, Boe AF, Boguski MS, Brockway
1720 KS, Byrnes E et al (2007) Genome-wide atlas of gene expression in the adult mouse brain.
1721 *Nature* 445: 168-176 Doi 10.1038/nature05453
- 1722 58 Li X, Lyu J, Li R, Jain V, Shen Y, Del Águila Á, Hoffmann U, Sheng H, Yang W (2022) Single-cell
1723 transcriptomic analysis of the immune cell landscape in the aged mouse brain after ischemic
1724 stroke. *J Neuroinflammation* 19: 83 Doi 10.1186/s12974-022-02447-5
- 1725 59 Liddel SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML,
1726 Münch AE, Chung WS, Peterson TC et al (2017) Neurotoxic reactive astrocytes are induced by
1727 activated microglia. *Nature* 541: 481-487 Doi 10.1038/nature21029
- 1728 60 Liu X, Hu R, Pei L, Si P, Wang C, Tian X, Wang X, Liu H, Wang B, Xia Z et al (2020) Regulatory T
1729 cell is critical for interleukin-33-mediated neuroprotection against stroke. *Exp Neurol* 328:
1730 113233 Doi 10.1016/j.expneurol.2020.113233
- 1731 61 Lv Y, Zhang B, Zhai C, Qiu J, Zhang Y, Yao W, Zhang C (2015) PFKFB3-mediated glycolysis is
1732 involved in reactive astrocyte proliferation after oxygen-glucose deprivation/reperfusion and
1733 is regulated by Cdh1. *Neurochem Int* 91: 26-33 Doi 10.1016/j.neuint.2015.10.006
- 1734 62 Maitra M, Nagy C, Chawla A, Wang YC, Nascimento C, Suderman M, Thérout JF, Mechawar
1735 N, Ragoussis J, Turecki G (2021) Extraction of nuclei from archived postmortem tissues for
1736 single-nucleus sequencing applications. *Nat Protoc* 16: 2788-2801 Doi 10.1038/s41596-021-
1737 00514-4
- 1738 63 Marsh SE (2021) scCustomize: Custom Visualizations & Functions for Streamlined Analyses of
1739 Single Cell Sequencing. . v.1.1.1 <https://doi.org/10.5281/zenodo.5706430>.
1740 RRID:SCR_024675. edn, City
- 1741 64 Matsumura I, Tanaka H, Kanakura Y (2003) E2F1 and c-Myc in cell growth and death. *Cell*
1742 *Cycle* 2: 333-338
- 1743 65 Matusova Z, Hol EM, Pekny M, Kubista M, Valihrach L (2023) Reactive astrogliosis in the era
1744 of single-cell transcriptomics. *Front Cell Neurosci* 17: 1173200 Doi
1745 10.3389/fncel.2023.1173200
- 1746 66 McGinnis CS, Murrow LM, Gartner ZJ (2019) DoubletFinder: Doublet Detection in Single-Cell
1747 RNA Sequencing Data Using Artificial Nearest Neighbors. *Cell Syst* 8: 329-337.e324 Doi
1748 10.1016/j.cels.2019.03.003
- 1749 67 Mena H, Cadavid D, Rushing EJ (2004) Human cerebral infarct: a proposed histopathologic
1750 classification based on 137 cases. *Acta Neuropathol* 108: 524-530 Doi 10.1007/s00401-004-
1751 0918-z
- 1752 68 Micu I, Plemel JR, Capriarello AV, Nave KA, Stys PK (2018) Axo-myelinic neurotransmission: a
1753 novel mode of cell signalling in the central nervous system. *Nat Rev Neurosci* 19: 49-58 Doi
1754 10.1038/nrn.2017.128
- 1755 69 Morris R, Kershaw NJ, Babon JJ (2018) The molecular details of cytokine signaling via the
1756 JAK/STAT pathway. *Protein Sci* 27: 1984-2009 Doi 10.1002/pro.3519

- 1757 70 Neely SA, Williamson JM, Klingseisen A, Zoupi L, Early JJ, Williams A, Lyons DA (2022) New
1758 oligodendrocytes exhibit more abundant and accurate myelin regeneration than those that
1759 survive demyelination. *Nat Neurosci* 25: 415-420 Doi 10.1038/s41593-021-01009-x
- 1760 71 Noritake J, Watanabe T, Sato K, Wang S, Kaibuchi K (2005) IQGAP1: a key regulator of
1761 adhesion and migration. *J Cell Sci* 118: 2085-2092 Doi 10.1242/jcs.02379
- 1762 72 Padamsey Z, Rochefort NL (2023) Paying the brain's energy bill. *Curr Opin Neurobiol* 78:
1763 102668 Doi 10.1016/j.conb.2022.102668
- 1764 73 Pandey S, Shen K, Lee SH, Shen YA, Wang Y, Otero-García M, Kotova N, Vito ST, Laufer BI,
1765 Newton DF et al (2022) Disease-associated oligodendrocyte responses across
1766 neurodegenerative diseases. *Cell Rep* 40: 111189 Doi 10.1016/j.celrep.2022.111189
- 1767 74 Piao JH, Wang Y, Duncan ID (2013) CD44 is required for the migration of transplanted
1768 oligodendrocyte progenitor cells to focal inflammatory demyelinating lesions in the spinal
1769 cord. *Glia* 61: 361-367 Doi 10.1002/glia.22438
- 1770 75 Piwecka M, Rajewsky N, Rybak-Wolf A (2023) Single-cell and spatial transcriptomics:
1771 deciphering brain complexity in health and disease. *Nat Rev Neurol* 19: 346-362 Doi
1772 10.1038/s41582-023-00809-y
- 1773 76 Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown
1774 M, Demaerschalk BM, Hoh B et al (2019) Guidelines for the Early Management of Patients
1775 With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management
1776 of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart
1777 Association/American Stroke Association. *Stroke* 50: e344-e418 Doi
1778 10.1161/str.0000000000000211
- 1779 77 Qi Y, Cai J, Wu Y, Wu R, Lee J, Fu H, Rao M, Sussel L, Rubenstein J, Qiu M (2001) Control of
1780 oligodendrocyte differentiation by the Nkx2.2 homeodomain transcription factor.
1781 *Development* 128: 2723-2733 Doi 10.1242/dev.128.14.2723
- 1782 78 Qian Z, Qin J, Lai Y, Zhang C, Zhang X (2023) Large-Scale Integration of Single-Cell RNA-Seq
1783 Data Reveals Astrocyte Diversity and Transcriptomic Modules across Six Central Nervous
1784 System Disorders. *Biomolecules* 13: Doi 10.3390/biom13040692
- 1785 79 Qin C, Yang S, Chu YH, Zhang H, Pang XW, Chen L, Zhou LQ, Chen M, Tian DS, Wang W (2022)
1786 Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic
1787 interventions. *Signal Transduct Target Ther* 7: 215 Doi 10.1038/s41392-022-01064-1
- 1788 80 Rakers C, Schleif M, Blank N, Matušková H, Ulas T, Händler K, Torres SV, Schumacher T, Tai K,
1789 Schultze J et al (2019) Stroke target identification guided by astrocyte transcriptome
1790 analysis. *Glia* 67: 619-633 Doi 10.1002/glia.23544
- 1791 81 Ruediger T, Zimmer G, Barchmann S, Castellani V, Bagnard D, Bolz J (2013) Integration of
1792 opposing semaphorin guidance cues in cortical axons. *Cereb Cortex* 23: 604-614 Doi
1793 10.1093/cercor/bhs044
- 1794 82 Sakai S, Shichita T (2019) Inflammation and neural repair after ischemic brain injury.
1795 *Neurochem Int* 130: 104316 Doi 10.1016/j.neuint.2018.10.013
- 1796 83 Sawada R, Nakano-Doi A, Matsuyama T, Nakagomi N, Nakagomi T (2020) CD44 expression in
1797 stem cells and niche microglia/macrophages following ischemic stroke. *Stem Cell Investig* 7: 4
1798 Doi 10.21037/sci.2020.02.02
- 1799 84 Schirmer L, Velmeshev D, Holmqvist S, Kaufmann M, Werneburg S, Jung D, Vistnes S, Stockley
1800 JH, Young A, Steindel M et al (2019) Neuronal vulnerability and multilineage diversity in
1801 multiple sclerosis. *Nature* 573: 75-82 Doi 10.1038/s41586-019-1404-z
- 1802 85 Shankar SL, O'Guin K, Kim M, Varnum B, Lemke G, Brosnan CF, Shafit-Zagardo B (2006)
1803 Gas6/Axl signaling activates the phosphatidylinositol 3-kinase/Akt1 survival pathway to
1804 protect oligodendrocytes from tumor necrosis factor alpha-induced apoptosis. *J Neurosci* 26:
1805 5638-5648 Doi 10.1523/jneurosci.5063-05.2006
- 1806 86 Shen XY, Gao ZK, Han Y, Yuan M, Guo YS, Bi X (2021) Activation and Role of Astrocytes in
1807 Ischemic Stroke. *Front Cell Neurosci* 15: 755955 Doi 10.3389/fncel.2021.755955

- 1808 87 Shi L, Sun Z, Su W, Xu F, Xie D, Zhang Q, Dai X, Iyer K, Hitchens TK, Foley LM et al (2021) Treg
1809 cell-derived osteopontin promotes microglia-mediated white matter repair after ischemic
1810 stroke. *Immunity* 54: 1527-1542.e1528 Doi 10.1016/j.immuni.2021.04.022
- 1811 88 Shin SY, Song H, Kim CG, Choi YK, Lee KS, Lee SJ, Lee HJ, Lim Y, Lee YH (2009) Egr-1 is
1812 necessary for fibroblast growth factor-2-induced transcriptional activation of the glial cell
1813 line-derived neurotrophic factor in murine astrocytes. *J Biol Chem* 284: 30583-30593 Doi
1814 10.1074/jbc.M109.010678
- 1815 89 Silvin A, Uderhardt S, Piot C, Da Mesquita S, Yang K, Geirsdottir L, Mulder K, Eyal D, Liu Z,
1816 Bridlance C et al (2022) Dual ontogeny of disease-associated microglia and disease
1817 inflammatory macrophages in aging and neurodegeneration. *Immunity* 55: 1448-1465.e1446
1818 Doi 10.1016/j.immuni.2022.07.004
- 1819 90 Spitzer D, Guérit S, Puetz T, Khel MI, Armbrust M, Dunst M, Macas J, Zinke J, Devraj G, Jia X et
1820 al (2022) Profiling the neurovascular unit unveils detrimental effects of osteopontin on the
1821 blood-brain barrier in acute ischemic stroke. *Acta Neuropathol* 144: 305-337 Doi
1822 10.1007/s00401-022-02452-1
- 1823 91 Steelman AJ, Zhou Y, Koito H, Kim S, Payne HR, Lu QR, Li J (2016) Activation of
1824 oligodendroglial Stat3 is required for efficient remyelination. *Neurobiol Dis* 91: 336-346 Doi
1825 10.1016/j.nbd.2016.03.023
- 1826 92 Sung HY, Chen WY, Huang HT, Wang CY, Chang SB, Tzeng SF (2019) Down-regulation of
1827 interleukin-33 expression in oligodendrocyte precursor cells impairs oligodendrocyte lineage
1828 progression. *J Neurochem* 150: 691-708 Doi 10.1111/jnc.14788
- 1829 93 Trapnell C, Cacchiarelli D, Grimsby J, Pokharel P, Li S, Morse M, Lennon NJ, Livak KJ,
1830 Mikkelsen TS, Rinn JL (2014) The dynamics and regulators of cell fate decisions are revealed
1831 by pseudotemporal ordering of single cells. *Nat Biotechnol* 32: 381-386 Doi
1832 10.1038/nbt.2859
- 1833 94 Türei D, Valdeolivas A, Gul L, Palacio-Escat N, Klein M, Ivanova O, Ölbei M, Gábor A, Theis F,
1834 Módos D et al (2021) Integrated intra- and intercellular signaling knowledge for multicellular
1835 omics analysis. *Mol Syst Biol* 17: e9923 Doi 10.15252/msb.20209923
- 1836 95 Vay SU, Olschewski DN, Petereit H, Lange F, Nazarzadeh N, Gross E, Rabenstein M, Blaschke
1837 SJ, Fink GR, Schroeter M et al (2021) Osteopontin regulates proliferation, migration, and
1838 survival of astrocytes depending on their activation phenotype. *J Neurosci Res* 99: 2822-2843
1839 Doi 10.1002/jnr.24954
- 1840 96 Verkhatsky A, Nedergaard M (2018) Physiology of Astroglia. *Physiol Rev* 98: 239-389 Doi
1841 10.1152/physrev.00042.2016
- 1842 97 Wei H, Wu X, Withrow J, Cuevas-Diaz Duran R, Singh S, Chaboub LS, Rakshit J, Mejia J, Rolfe
1843 A, Herrera J et al (2023) Glial progenitor heterogeneity and key regulators revealed by single-
1844 cell RNA sequencing provide insight to regeneration in spinal cord injury. *Cell Rep* 42: 112486
1845 Doi 10.1016/j.celrep.2023.112486
- 1846 98 Wickham H (2016) Data Analysis. In: Wickham H (ed) *ggplot2: Elegant Graphics for Data*
1847 *Analysis*. Springer International Publishing, City, pp 189-201
- 1848 99 Xiao Y, Czopka T (2023) Myelination-independent functions of oligodendrocyte precursor
1849 cells in health and disease. *Nat Neurosci* 26: 1663-1669 Doi 10.1038/s41593-023-01423-3
- 1850 100 Xie D, Liu H, Xu F, Su W, Ye Q, Yu F, Austin TJ, Chen J, Hu X (2021) IL33 (Interleukin 33)/ST2
1851 (Interleukin 1 Receptor-Like 1) Axis Drives Protective Microglial Responses and Promotes
1852 White Matter Integrity After Stroke. *Stroke* 52: 2150-2161 Doi
1853 10.1161/strokeaha.120.032444
- 1854 101 Xu S, Lu J, Shao A, Zhang JH, Zhang J (2020) Glial Cells: Role of the Immune Response in
1855 Ischemic Stroke. *Front Immunol* 11: 294 Doi 10.3389/fimmu.2020.00294
- 1856 102 Young MD, Behjati S (2020) SoupX removes ambient RNA contamination from droplet-based
1857 single-cell RNA sequencing data. *Gigascience* 9: Doi 10.1093/gigascience/giaa151
- 1858 103 Zamanian JL, Xu L, Foo LC, Nouri N, Zhou L, Giffard RG, Barres BA (2012) Genomic analysis of
1859 reactive astroglia. *J Neurosci* 32: 6391-6410 Doi 10.1523/jneurosci.6221-11.2012

- 1860 104 Zeisel A, Hochgerner H, Lönnerberg P, Johnsson A, Memic F, van der Zwan J, Häring M, Braun
1861 E, Borm LE, La Manno Get al (2018) Molecular Architecture of the Mouse Nervous System.
1862 Cell 174: 999-1014.e1022 Doi 10.1016/j.cell.2018.06.021
1863 105 Zheng K, Lin L, Jiang W, Chen L, Zhang X, Zhang Q, Ren Y, Hao J (2022) Single-cell RNA-seq
1864 reveals the transcriptional landscape in ischemic stroke. J Cereb Blood Flow Metab 42: 56-73
1865 Doi 10.1177/0271678x211026770
1866 106 Zou C, Luo Q, Qin J, Shi Y, Yang L, Ju B, Song G (2013) Osteopontin promotes mesenchymal
1867 stem cell migration and lessens cell stiffness via integrin β 1, FAK, and ERK pathways. Cell
1868 Biochem Biophys 65: 455-462 Doi 10.1007/s12013-012-9449-8

1869

1870

1871

1872

1873

1874

1875

1876

1877

1878

1879

1880

1881

1882

1883

1884

1885

1886

1887

1888

1889

1890

1891

1892

1893

1894 **Data availability statement**

1895 Single nucleus RNA-seq datasets reported in the present paper will be made publicly
1896 available via the NCBI-GEO database, after completion of peer review and publication.
1897 All other raw data supporting the herein made conclusions is available upon
1898 reasonable request.

1899 **Funding**

1900 This work was supported by the Austrian Research Promotion Agency (#852748,
1901 #862068), the Vienna Business Agency (#2343727) and the Aposcience AG. This
1902 study was also supported by VASCage – Centre on Clinical Stroke Research.
1903 VASCage is a COMET Centre within the Competence Centers for Excellent
1904 Technologies (COMET) programme and funded by the Federal Ministry for Climate
1905 Action, Environment, Energy, Mobility, Innovation and Technology, the Federal
1906 Ministry of Labour and Economy, and the federal states of Tyrol, Salzburg and Vienna.
1907 COMET is managed by the Austrian Research Promotion Agency (Österreichische
1908 Forschungsförderungsgesellschaft) - FFG Project number: 898252. SH gratefully
1909 acknowledges funding by the National Institutes of Health (1R01NS114227-01A1 to
1910 SH). SzN and GBB were supported by the Austrian Science Fund (FWF), grant
1911 numbers T1091, P31085-B26.

1912 **Conflict of interest**

1913 The authors declare that the research has been performed without any conflict of
1914 interest.

1915 **Author contributions**

1916 DB and MM: conceptualization – overall design of the study. DB, MK, CO, SzN, GBB,
1917 SK, HJA, MM: conceptualization/methodology – design of *in vivo* experiments, sample
1918 acquisition and general analysis strategy. CO, AL, AC: investigation – execution of *in*
1919 *vivo* MCAO and MRI experiments. DB, DC, KK, MD: investigation – scRNAseq
1920 experiments. DB, EP, CJR, GT, PJ, BG, HK, MS, CH, VE: investigation –
1921 immunofluorescence staining experiments. DB, CJR, GT, HK, MS: investigation – cell
1922 culture experiments. DB, MK, CO, AL, AC, SzN, GBB, SK: formal analysis/data
1923 curation – MRI data. DB, EP, CJR, PJ, SH, RH, MM: formal analysis/data curation –
1924 immunofluorescence staining and cell culture data. DB: formal analysis and data
1925 curation – bioinformatics analyses. DB, DC, KK, MD: data curation/validation -
1926 bioinformatics analyses. HJA, MM: funding acquisition. HJA, MM: project

1927 administration. CO, SH, SK, RH, HJA, MM: resources. RH, SH, HJA, MM: supervision
1928 – HJA and MM supervised DB, RH and SH supervised CJR, GT, VE, CH. DB and MM:
1929 writing – original draft, visualization. All authors were involved in review & editing and
1930 approved of the final manuscript.

1931 **Acknowledgment**

1932 We would like to thank Hans Peter Haselsteiner and the CRISCAR Familienstiftung for
1933 their ongoing support of the Medical University/Aposcience AG public private
1934 partnership aiming to augment basic and translational clinical research in
1935 Austria/Europe. The authors acknowledge the core facilities of the Medical University
1936 of Vienna, a member of Vienna Life Science Instruments. We also thank Matthias
1937 Wielscher for his support in bioinformatics analyses and Irene Erber and the team of
1938 Matthias Farlik-Födinger for their invaluable technical support.

1939